Pharmaceutical composition for topical application

Information

  • Patent Grant
  • 8512718
  • Patent Number
    8,512,718
  • Date Filed
    Friday, February 12, 2010
    14 years ago
  • Date Issued
    Tuesday, August 20, 2013
    11 years ago
Abstract
A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.
Description
FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to a pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum). More particularly, the present invention relates to (i) a cosmetic or pharmaceutical carrier or composition characterized by rheological properties which render the carrier or composition semi-solid at rest and liquid upon application of shear forces (e.g., spread forces) thereto; (ii) methods of preparing same; and (iii) methods of utilizing same for treating a variety of skin or mucosal membrane diseases or disorders.


Most of the skin or mucosal membrane diseases or disorders are the result of inflammation caused by inflammatory agents, such as, but not limited to, bacterial, fungal, viral, parasitic, autoimmune, allergic, hormonal and/or malignant inflammatory agents. The most common skin diseases or disorders include eczema, psoriasis and dermatitis, including contact dermatitis, atopic dermatitis and seborrheic dermatitis.


Eczema and dermatitis result from inflammatory processes that involve the upper dermis and epidermis of the skin. When eczema develops, the keratinocytes in the epidermis distend from one another and fluid is accumulated there amongst in a process known as spongiosis.


In chronic forms of eczema or dermatitis the main change include thickening of the epidermis, which leads to itching, roughening and scaling of the skin surface. The loss of water from the skin leads to inflammation of the horny layer, which later result in cracked and sore skin.


Dermatitis is further classified into contact dermatitis (allergic or non allergic), atopic dermatitis and seborrheic dermatitis.


Non allergic contact dermatitis occurs in response to skin irritants, such as acids, alkalis, oils, detergents and solvents.


Allergic contact dermatitis occurs as a result of sensitization to repeated exposure to an antigen. Allergic contact dermatitis appears in skin areas that were in direct contact with the antigen.


Atopic dermatitis, which affects mainly infants, is characterized by sensitization of the skin to a wide range of common antigens.


Seborrheic dermatitis affects the scalp and other hairy areas, the face, and flexural areas and results from yeast or bacteria induced inflammation. Most people suffer from dandruff which is a mild form of seborrheic dermatitis.


Psoriasis is a dominant autosomal inherited inflammatory disease characterized by enhanced proliferation of keratinocytes which proliferation leads to formation of scaly plaques on, for example, the knees, elbows, buttocks, and which are esthetically unpleasant and cause discomfort to the affected subject.


Skin diseases or disorders are usually treated by creams, gels or ointments containing antifungal agents, steroidal agents and/or antibacterial agents. In many instances such creams, gels and ointments are difficult to spread, result in a greasy and sticky appearance and are usually not appealing for use.


Genital infections are caused by fungal, viral and microbial agents. Genital infections are treated either systematically, or by the use of creams, ointments or pessaries, which usually leak or otherwise fail to spread well and lead to ineffective therapeutic concentration of the therapeutically active agent(s) therein.


Genital herpes infections are widespread from the 70's and apart from the discomfort they inflict, genital herpes infections may, in some cases, develop into severe disease. Presently, there is no effective medication for genital herpes.


Trichomoniasis is an infection of the urogenital tract caused due to infection by the protozoan Trichomonas vaginalis. Trichomoniasis is associated with uncomfort itching and vaginal excretion in women.


Candidiasis is caused by Candida albicans and results in itching in the genital area and white discharge therefrom.


Mucosal membrane inflammations can affect other organs such as for example, the eye. Conjunctivitis, caused by different types of bacteria, such as, but not limited to, Staphylococcus aureus, Streptococcus pneumoniae or Haemophilus influenzae, is generally treated with antibiotic ointments, e.g., bacitracin 500 U/g or gentamicin 0.3 percent ophthalmic ointment instilled into the affected eye. The compliance to these ointments is usually poor due to the sticky feeling they exert.


As is evident from the above descriptions, one of the important routes of administration of a drug for treating a skin or mucosal membrane is by topical application of a drug onto the skin or mucosal membrane. This method is useful for local treatment but it is also possible to apply pessaries via the rectum as an efficient delivery method of systemic agents that are not degraded in the intestine.


Many pharmaceutical carriers are presently known, most of them have disadvantages when topically applied onto the skin or mucosal membranes. For example, when ointments containing petroleum as a carrier are applied onto a skin wound, metabolic products and excreta from the wound cannot be easily removed therefrom because of the difficulty of passing through the hydrophobic petroleum barrier. In addition, the active drug ingredient, which is dissolved or dispersed in the petroleum carrier, is not efficiently absorbed into the wound tissue, thus, the efficacy of the drug is affected. Another example is ophthalmologic ointments, which are applied into the eye, and make the eye area sticky and uncomfortable. Moreover, in physiological aspect, petroleum restricts respiration of a wound tissue and is disturbing to the normal respiration of the skin.


Many groups of drugs including, for example, antibiotic, antifungal, antiinflammatory, anesthetic, analgesic, antiallergic, corticosteroid, retinoid and antiproliferative medications are preferably administered typically using a hydrophobic carrier such as petroleum. However, due to the undesirable consistency of petroleum and similar hydrophobic carriers, their topical use is limited. An additional disadvantage of petroleum-carrier including products relates to the greasy feeling following their topical application to the skin or mucosal membranes.


Besides petroleum, other hydrophobic pharmaceutical carriers are known, including liquid paraffin, lanolin, beeswax, vegetable oil, glycerin monostearate, higher alcohols, polyethylene glycol and some emulsifying agents. All of these agents either suffer the limitations described hereinabove with respect to petroleum or have undesirable (fast) flow properties.


Several hydrophobic liquids, e.g., mono- and poly-unsaturated oils from vegetable and marine sources, silicone oils, mineral oils, and liquid hydrophobic plant-derived oils are known for their therapeutic effects when applied topically. Oils may also contain essential nutritional constituents, such as oil-soluble vitamins (e.g., vitamin A and vitamin E), minerals and other therapeutically effective constituents. Administration of such therapeutic oils in a liquid form does not exert sufficient amounts of the therapeutic agents, because of the oil flow-spread properties. Other examples of therapeutic oils include mineral and silicone oils, which are useful for the treatment of skin dehydration and other medical diseases or disorders. These oils are also liquid at ambient temperature.


There is thus a widely recognized need for, and it would be highly advantageous to have a new pharmaceutical or cosmetic composition or carrier which is semi-solid at rest and which liquefies upon application of shear forces thereto, because such a pharmaceutical or cosmetic composition or carrier can be topically applied as a semi-solid onto an affected area and then turn into a liquid upon spreading, resulting in faster absorption and less greasiness and stickiness.


SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided a pharmaceutical or cosmetic carrier comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent.


According to another aspect of the present invention there is provided a method of preparing a pharmaceutical or cosmetic carrier, the method comprising the steps of mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight; and cooling the mixture.


According to yet another aspect of the present invention there is provided a pharmaceutical or cosmetic composition comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of the solidifying agent and the hydrophobic solvent has a therapeutic or cosmetic beneficial effect.


According to still another aspect of the present invention there is provided a pharmaceutical or cosmetic composition comprising (a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent; and (b) a therapeutically or cosmetically effective amount of a biologically active substance.


According to an additional aspect of the present invention there is provided a method of preparing a pharmaceutical or cosmetic composition, the method comprising the steps of mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a pharmaceutical or cosmetic mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight and further mixing into the mixture a therapeutically or cosmetically effective amount of a biologically active substance.


According to yet an additional aspect of the present invention there is provided a method of treating a disease or disorder of a skin or a mucosal membrane, the method comprising the step of topically administrating to the skin or the mucosal membrane a pharmaceutical or cosmetic composition containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of the solidifying agent and the hydrophobic solvent has a therapeutic or cosmetic beneficial effect.


According to a further aspect of the present invention there is provided a method of treating a disease or disorder of a skin or a mucosal membrane, the method comprising the step of topically administrating to the skin or the mucosal membrane a pharmaceutical or cosmetic composition containing (a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent; and (b) a therapeutically or cosmetically effective amount of a biologically active substance.


According to further features in preferred embodiments of the invention described below, the solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.


According to still further features in the described preferred embodiments the solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.


According to still further features in the described preferred embodiments the hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.


According to still further features in the described preferred embodiments the hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.


According to still further features in the described preferred embodiments the hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.


According to still further features in the described preferred embodiments the solidifying agent has at least one alkyl group side chain in its carbon backbone.


According to still further features in the described preferred embodiments the carbon backbone of the fatty acid and/or the fatty alcohol has at least one hydroxyl group at position α or β.


According to still further features in the described preferred embodiments the carbon backbone of the fatty acid or the fatty alcohol has at least one hydroxyl group at positions 8-14.


According to still further features in the described preferred embodiments the solidifying agent includes a 12-hydroxy fatty acid.


According to still further features in the described preferred embodiments at least one of the solidifying agent and the hydrophobic solvent have a therapeutic or cosmetic beneficial effect.


According to still further features in the described preferred embodiments the skin or the mucosal membrane disease or disorder includes inflammation caused by an inflammatory agent selected from the group consisting of a bacterial inflammatory agent, a fungal inflammatory agent, a viral inflammatory agent, a parasitic inflammatory agent, an autoimmune inflammatory agent, an allergic inflammatory agent, a hormonal inflammatory agent and a malignant inflammatory agent.


According to still further features in the described preferred embodiments the skin disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, itching, wounds, burns, cuts, ulcers, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.


According to still further features in the described preferred embodiments the statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and the exfoliative dermatitis is erythroderma.


According to still further features in the described preferred embodiments the biologically active substance is selected from the group consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, a protease inhibitor, a non-steroidal antiinflammatory drug, an immunosuppressant, an antihistamine agent, an antiinflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.


According to still further features in the described preferred embodiments (a) the antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactames, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clindamycin; (b) the free radical generating agent is benzoyl peroxide; (c) the antifungal agent is selected from the group consisting of azoles, diazole, triazole, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide; (d) the antiviral agent is selected from the group of flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir; (e) the nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovudine, Stavudine and Lamivudine; (f) the non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine; (g) the protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon; (h) the immunosuppressant is selected from the group consisting of Clobetasol proprionate, Halobetasol proprionate, Betamethasone diproprionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene; (i) the antiinflammatory agent is a vitamin B3 derivative; (j) the retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin; (k) the tar agent is selected from the group consisting of coal tar and cade oil; (l) the antihistamine agent is doxepine hydrochloride; (m) the antipruritic agent is crotampiton; and (n) the scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.


According to still further features in the described preferred embodiments the biologically active substance is effective in the treatment of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis or exfoliative dermatitis.


According to still further features in the described preferred embodiments the statis dermatitis is selected from the group consisting of gravitational eczema; varicose eczema, whereas the exfoliative dermatitis is erythroderma.


The present invention successfully addresses the shortcomings of the presently known configurations by providing a biologically active carrier or composition, which is semi solid at rest and liquefies upon application of shear forces thereto, which is therefore easy to spread, highly absorbable, non greasy and non-sticky and which can be used for the treatment of a great number of diseases and syndromes affecting the skin and mucosal membranes.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawing.



FIG. 1 is a photograph demonstrating the therapeutic effects of a corticosteroid composition prepared in accordance with the teachings of the present invention administered twice a day for 10 days, to a psoriasis patient. The composition was prepared as described in Example 1. The photograph clearly demonstrates a reduction in the psoriatic plaques size following the course of treatment.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of (i) a pharmaceutical or cosmetic carrier or composition for topical application, preferably characterized by rheological properties which render the carrier or composition a semi-solid at rest and a liquid upon application of shear forces thereto; (ii) methods of preparing same; and (iii) methods of utilizing same for treating skin or mucosal membrane diseases or disorders.


The principles and operation of the present invention may be better understood with reference to the accompanying descriptions and examples.


Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of composition set forth in the following description or examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.


According to one aspect of the present invention there is provided a pharmaceutical or cosmetic carrier comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, which solvent per se is typically liquid at ambient temperature.


As used herein in the specification and in the claims section that follows, the term “carrier” means a base which is, as is defined in the Collins dictionary, the main ingredient of a mixture. Thus, as used herein a “pharmaceutical carrier” is a pharmaceutical base which is used in the preparation of pharmaceutical compositions, whereas a “cosmetic carrier” is a cosmetic base which is used in the preparation of cosmetic compositions.


According to another aspect of the present invention there is provided a method of preparing a pharmaceutical or cosmetic carrier. The method according to this aspect of the invention is effected by mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight; and cooling the mixture, e.g., to room temperature. Preferably, prior to the step of mixing, both the hydrophobic solvent and the solidifying agent are brought to the temperature above the melting temperature of the solidifying agent.


According to still another aspect of the present invention there is provided a pharmaceutical or cosmetic composition comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of the solidifying agent and/or the hydrophobic solvent has a therapeutic or cosmetic beneficial effect.


According to yet another aspect of the present invention there is provided a method of preparing a pharmaceutical or cosmetic composition. The method according to this aspect of the invention is effected by mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight; and cooling the mixture, e.g., to room temperature. Preferably, prior to the step of mixing, both the hydrophobic solvent and the solidifying agent are brought to the temperature above the melting temperature of the solidifying agent, e.g., 60-80° C.


Thus, the present invention offers a method of treating a disease or disorder of a skin or a mucosal membrane, such as, but not limited to, a mucosa of a nose, a mucosa of a mouth, a mucosa of an eye, a mucosa of an ear, a mucosa of a vagina and a mucosa of a rectum. The method according to this aspect of the present invention is effected by topically administrating to the skin or the mucosal membrane a pharmaceutical or cosmetic composition containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of the solidifying agent and the hydrophobic solvent has a therapeutic or cosmetic beneficial effect.


Most preferably, the amount of the solidifying agent in a pharmaceutical or cosmetic carrier according to the present invention is about 4 percent to about 12 percent, whereas the amount of the hydrophobic solvent is about 88 percent to about 96 percent of the total weight of the carrier. As used herein the term about refers to ±20%.


According to a preferred embodiment of the present invention, the solidifying agent includes at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and/or at least one fatty acid, having at least 18 carbon atoms in its carbon backbone. Preferably, the solidifying agent has at least one alkyl group side chain in its carbon backbone. Additionally or alternatively, the carbon backbone of the fatty acid or the fatty alcohol has at least one hydroxyl group at position α and β. Still additionally or alternatively, the carbon backbone of the fatty acid or the fatty alcohol has at least one hydroxyl group at positions 8-14. According to presently preferred embodiments of the invention, the solidifying agent preferably includes a 12-hydroxy fatty acid.


According to another preferred embodiment of the present invention, the solidifying agent includes a substance selected such that ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto, i.e., has thixotropic properties.


As mentioned above, preferred solidifying agents, according to the present invention, include fatty alcohols having 15 or more carbons in their carbon chain, such as acetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols include arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (e.g., up to C50). The concentration of the fatty alcohol, required to obtain the thixotropic properties is inversely related to the length of its carbon chains.


Fatty alcohols, derived from beeswax, comprising a mixture of alcohols, where the majority have at least 20 carbon atoms in their carbon chain, are especially suited as solidifying agents according to the present invention.


Another preferred class of solidifying agents includes fatty acids having 18 or more carbons in their carbon chain, such as and stearic acid, arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (e.g., up to C50), or mixtures thereof.


The concentration of the fatty acid required to obtain a thickened carrier is inversely related to the length of its carbon chains. Stearic acid, for example, exerts a considerable thickening effect at about 10 percent concentration, whereas behenic acid would obtain the same thickening effect at a 5 percent concentration.


Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond.


A further class of solidifying agent according to the present invention comprises long chain fatty alcohols or fatty acids, wherein the carbon atom chain is branched. In an additional preferred class of solidifying agents, the carbon chain of the fatty acid is substituted with a hydroxyl group, e.g., 12 hydroxy stearic acid.


An important property of the fatty alcohols and fatty acids used in context of the carrier and composition of the present invention is related to their therapeutic properties per se. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, U.S. Pat. No. 4,874,794, which is incorporated herein by reference). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc., are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess antiinfective characteristics. Thus, the pharmaceutical or cosmetic carrier of the present invention provides an extra therapeutic or cosmetic benefit in comparison with currently used vehicles, such as petroleum, which are inert and non-active.


According to still another preferred embodiment of the present invention, the hydrophobic solvent includes at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and/or at least one plant-derived oil. Examples include, but are not limited to, olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and/or jojova oil.


As used herein “tea tree oil” or “melaleuca oil” both refer to distillates of the leaves of the Australian tree, Melaleuca alternifolia. Tea tree oil is assigned the Chemical Abstract number 68647-73-4 and is commercially available from a variety of sources. Tea tree oil is recognized as having properties as a solvent, antiseptic, antibacterial, antifungal, and pain reliever, as well as other uses. Melaleuca oil has been used in soaps, shampoos, hand creams, tooth pastes, and household cleaners, as well as for treatment of warts and oral candidiasis.


A particularly preferred class of oils to be used in context of the present invention include poly-unsaturated oils which contains omega-3 and omega-6 fatty acids. Thus, in a presently most preferred embodiment of the present invention the carrier contains at least 6 percent omega-3 oil and/or omega-6 oil.


The above described pharmaceutical or cosmetic carrier may be used in the preparation of a pharmaceutical or cosmetic composition comprising (a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, which is typically liquid at ambient temperature; and (b) a therapeutically or cosmetically effective amount of a biologically active substance. Preferably, at least one of the solidifying agent and the hydrophobic solvent has a therapeutic or cosmetic beneficial effect.


As used herein in the specification and in the claims section that follows the phrase “biologically active substance” refers to an active ingredient which has a therapeutic or cosmetic effect following its administration to an organism (human or animal). The therapeutic or cosmetic effect can be curing, minimizing, preventing or ameliorating a disease or disorder, or improving the physical appearance and aesthetics (e.g., skin hydration) or may have any other therapeutic or cosmetic beneficial effect. The biologically active substance may be, for example, a drug, a vitamin or a vaccine. Thus, the biologically active substances employed in context of the present invention are generally selected from the broad categories of medicaments, agricultural products and cosmetic products. The biologically active substance may be a single drug or a combination of drugs that are dissolved or spread in the carrier of the present invention. Therefore, they are usually, yet not obligatorily, hydrophobic. The concentration of the substance is selected so as to exert its therapeutic or cosmetic effect.


According to another aspect of the invention there is provided a method of preparing a pharmaceutical or cosmetic composition. The method according to this aspect of the present invention is effected by (a) mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a pharmaceutical or cosmetic mixture containing 75-99 percent of the hydrophobic solvent by weight, and 1-25 percent of the solidifying agent by weight; and (b) further mixing into the carrier mixture a therapeutically or cosmetically effective amount of a biologically active substance. Preferably, prior to the step of mixing, both the hydrophobic solvent and the solidifying agent are brought to the temperature above the melting temperature of the solidifying agent, e.g., 60-80° C.


According to a preferred embodiment of this aspect of the present invention the biologically active substance is an antibiotic agent, e.g., chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactames, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clindamycin; a free radical, e.g., benzoyl peroxide; a generating agent; an antifungal agent, e.g., azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide; an antiviral agent, e.g., flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir; a non-nucleoside reverse transcriptase inhibitor, Nevirapine and Delavirdine; a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, e.g., e.g., Zidovudine, Stavudine and Lamivudine, a protease inhibitor, e.g., Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon; a non-steroidal antiinflammatory drug, e.g., Voltarene; an immuno, e.g., Clobetasol proprionate, Halobetasol proprionate, Betamethasone diproprionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene; an antihistamine, e.g., doxepine hydrochloride; an antiinflammatory agent, e.g., vitamin B3 or a derivative thereof; a retinoid agent, e.g., isotretinoin, adapalene and tretinoin; a tar agent, e.g., coal tar and cade oil; an antipruritics agent, e.g., crotampiton; or a scabicide agent, e.g., benzyl benzoate, malathion and crotamiton.


The biologically active substance is preferably selected effective in the treatment of a disease or disorder, such as, but not limited to, psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis (e.g., gravitational eczema, varicose eczema) or exfoliative dermatitis (e.g., erythroderma).


Thus, the present invention offers another method of treating a disease or disorder of a skin or a mucosal membrane, such as, but not limited to, a mucosa of a nose, a mucosa of a mouth, a mucosa of an eye, a mucosa of an ear, a mucosa of a vagina and mucosa of a rectum. The method is effected by topically administrating thereto a pharmaceutical or cosmetic composition containing (a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, which is typically liquid at ambient temperature; and (b) a therapeutically or cosmetically effective amount of a biologically active substance.


The pH of the composition or carrier of the present invention is preferably maintained in the range of about pH 5.5-7.0. Acids, bases, and buffers can be used according to methods well known in the art for adjusting the pH of the carrier or composition.


Pharmaceutical compositions manufactured using the carrier according to the present invention are very easy to use. When applied on the afflicted body surface of humans or animals, they are in a semi-solid state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed. The ease of the application is demonstrated herein in Example 3, where it was compared, in a double blind test to a commercial hydrocortisone preparation. The subjects' score regarding their feeling about the preparation (e.g., the greasiness, stickiness, absorption, penetration, ease of spreading and lack of shiny look) was significantly higher than the score for the commercial preparation.


Additional particulars concerning the use of a variety of biologically active substances in context of the present invention, advantages of the present invention over prior art designs and a variety of applications of the present invention are provided hereinafter.


Treatment of Wounds:


The present invention may find special advantages in the treatment of wounds. Skin wounds which can be treated using the compositions of the present invention include burn wounds, sunburn, cuts, abrasions, acute and chronic wounds and the like. Treatment of burn, ulcers, acute and chronic wounds typically is directed to keeping the wound as clean as possible and making the patient as comfortable as possible. It has been recognized in this respect that keeping the wound moist is advantageous to patient comfort. While maintaining a moist environment will effect some cooling of the tissue, it would be advantageous to be able to decrease the intradermal temperature of a burn wound, which would help to alter the progression of the tissue damage due to heat within the tissues.


Accordingly, it would be advantageous to provide a method for improved treatment of a burn wound that permits significant lowering of the intradermal temperature of the burn wound such that the extent of the burn wound may be limited. Compositions which have antimicrobial agents combined with agents that lead to cooling effect, and which are devoid of adherence to the wound offer relief to people who are suffering from burns or ulcers. The present invention provides a protective moisture barrier to contribute to the sterility of the dressing and to maintain the moistness of the dressing. Sterility is enhanced by the bacteriostatic properties of the wound treatment composition, as well as the shielding action of the barrier's physical presence. An additional barrier to bacteria and contamination is the packaging utilized with the present invention and which is addressed in more detail below.


The wound treatment composition of the present invention comprises as the hydrophobic solvent, for example without limitation, tea tree oil, melaleuca oil and other ingredients in a thixotropic gel formulation. As stated hereinabove, Tea tree oil, or Melaleuca alternifolia, is a natural plant extract. The unique wound treatment composition, in addition to creating a moist, soothing environment, is also inherently bacteriostatic. It helps leave the surface of wounds clean and odor free. The odor of chronic wounds is a major concern of health care workers and caregivers. The effectiveness of Melaleuca is increased in the presence of blood and organic material, rather than decreased as is the case with other bacteriostatic products. Melaleuca oil is a natural oil which is considered to be safe and effective on all kinds of cuts and abrasions, surgical wounds, diabetic and mouth ulcers and foot fungi.


The application of the composition of the present invention onto cuts, wounds, burns and ulcers is beneficial both in the cure of an infection or in the protection of the skin from infection. In all such cases, the composition of the present invention is easy to use, being semi-solid when applied and becoming liquid instantly upon rubbing onto the skin.


Suppositories:


For treatment of vaginal infections, suppositories provide an effective mode for administration of a therapeutic agent. Although suppositories have attained some success, they have some disadvantages. Most of the current commercial vaginal suppositories, either melt or dissolve in the vaginal tract into an oily or aqueous liquid. This resulting liquid in turn tends to leak out or is expelled out of the vaginal cavity resulting either in soiled clothing and/or inferior efficacy. Accordingly, it is an object of the present invention to provide an effective antifungal suppository formulation, which overcomes the noted disadvantages associated with the prior art suppositories.


The suppository formulation of the invention is useful in treating vaginal fungus infections in mammalian species, such as humans, cats, dogs and the like. The suppository formulation will be easily inserted into the vaginal cavity and will melt at body temperature soon after insertion. Upon melting, the suppository turns into a gel/cream like consistency, which will adheres to the vaginal membrane thereby providing prolonged duration of effectiveness.


As mentioned above, a pharmaceutical or cosmetic composition in accordance with the teachings of the present invention may include a biologically active substance. The following provides some examples.


Antiviral Agents:


The carrier or composition of the present invention is beneficial in the treatment of viral infections. For example, cold sores are caused by the herpes simplex Type 1 virus and are sometimes referred to as facial herpes. Mollusca are small viral growths that appear singly or in groups on the face, trunk, lower abdomen, pelvis, inner thighs or penis. Shingles (herpes zoster), which usually only occurs once in a lifetime, appears as a rash (clusters of blisters with a red base). It is caused by the same virus responsible for chickenpox. Warts are a common, benign skin tumor caused by viral infection. Eye viral infections, such as viral conjunctivitis is highly contagious and spreads by droplet, fomites, and hand-to-eye inoculation.


Viral infections are currently treated with various antiviral agents, as is summarized in Table 1 below:









TABLE 1







Antiviral drugs











Chemical


Drug
Viruses
Type





Vidarabine
Herpesviruses
Nucleoside analog


Acyclovir
Herpes simplex (HSV)
Nucleoside analog


Gancyclovir
Cytomegalovirus (CMV)
Nucleoside analog


Nucleoside-analog reverse transcriptase
Retroviruses (HIV)
Nucleoside analog


inhibitors (NRTI): AZT (Zidovudine),


ddI (Didanosine), ddC (Zalcitabine), d4T


(Stavudine), 3TC (Lamivudine)


Non-nucleoside reverse transcriptase
Retroviruses (HIV)
Nucleoside analog


inhibitors (NNRTI): Nevirapine,


Delavirdine


Protease Inhibitors: Saquinavir,
HIV
Peptide analog


Ritonavir, Indinavir, Nelfinavir


Ribavirin
Broad spectrum: HCV,
Triazole carboxamide



HSV, measles, mumps,



Lassa fever


Amantadine/Rimantadine
Influenza A strains
Tricyclic amine


Interferons
Hepatitis B and C
Protein









It will be appreciated that the intrinsic antiviral effects of the solidifying agents, e.g., fatty alcohols and acids, provides a synergistic effect that will result in a higher therapeutic response.


Antiparasite Agents:


The biologically active substance contained in a composition of the present invention in a therapeutically effective amount may be an antiparasite agent, such as, but not limited to, hexachlorobenzene, carbamate, naturally occurring pyrethroids, permethrin, allethrin, malathion, piperonyl butoxide or mixtures of these drugs.


Antimicrobial Agents:


Antimicrobial agents, also referred to as germicidal agents, which may be used in compositions of the present invention include phenols, including cresols and resorcinols. Antibacterial compositions according to the present invention may be used to treat infections of the skin. An example of a very common skin infection is acne, which involve infestation of the sebaceous gland with p. acnes, as well as Staphylococus aurus or Pseudomonas. Various antibacterial agents have been utilized to treat acne, however, their efficacy is limited due to their low penetration into the hydrophobic environment of the sebaceous gland. The composition of the present invention, being hydrophobic by nature would facilitate an enhanced rate of penetration. Examples of useful antiacne actives include the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid, and resorcinol; retinoids such as retinoic acid and its derivatives (e.g., cis and trans); sulfur-containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, a preferred example of which is N-acetyl-L-cysteine; lipoic acid; antibiotics and antimicrobials such as benzoyl peroxide, octopirox, tetracycline, 2,4,4′-trichloro-2′-hydroxy diphenyl ether, 3,4,4′-trichlorobanilide, azelaic acid and its derivatives, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, ethyl acetate, clindamycin and meclocycline; sebostats such as flavonoids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate and cholate.


The intrinsic antibacterial and antiinflammatory effects of the solidifying agents, i.e., fatty alcohols and acids, of the composition of the present invention provide a combined synergetic effect that results in a better therapeutic response to treatment.


Eye infections are another preferred target for the composition of the present invention. Conjunctivitis, involving bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae is generally treated with antibiotic ointments, e.g., bacitracin 500 U/g or 0.3 percent ophthalmic ointment instilled into the affected eye. Yet, ointment applied into the eye created a sticky feeling and causes major disturbances to the patient. The composition of the present invention, which turns from semi-solid consistency into liquid instantly after application, does not have that disadvantage and thus, treatment compliance is expected to improve. The same advantage is expected when the composition of the present invention is topically applied to mucosal membranes, the oral cavity, the vagina or the rectum.


Another example is parachlorometaxylenol, which is an antimicrobial agent and is suitable for use in the compositions described in the present invention.


Phenols, in concentrations of about 0.2, 1.0, and 1.3 percent by weight are bacteriostatic, bactericidal, and fungicidal, respectively. While it is not intended that the present invention be bound by any particular theory, it is believed that the germicidal action of phenols at these concentrations is effected through protein denaturation. The phenol-protein interaction is relatively weak, allowing the phenol molecule to penetrate deeply into the tissue. Thus, phenol can penetrate relatively dense, intact keratinous matrices, such as the stratum corneum or the nail plate. Several phenol derivatives are more potent than phenol itself, and the most important among these are the halogenated phenols and bis-phenols, the alkyl-substituted phenols and the resorcinols.


Optionally, the present invention may provide a solution for body odors by including hydrophobic antibacterial compounds to help destroy and/or control the amount of bacteria present on the skin, which aids in body odor control.


Hydrophobic antibacterials useful in the present invention include triclosan, triclocarbon, eucalyptol, menthol, methylsalicylate, thymol, and mixtures thereof. Preferred are triclosan and triclocarbon. When included in the composition of the present invention, the hydrophobic antibacterials may be at a level of from about 0.1 percent to about 1.5 percent and preferably from about 0.1 percent to about 0.3 percent, by weight of the composition.


Antifungal Agents:


Fungal infections are another object of treatment using the compositions of the present invention. Superficial fungal infection of the skin is one of the commonest skin disease seen in general practice. Dermatophytosis is probably the most common superficial fungal infection of the skin. It is caused by a group of fungi, which are capable of metabolizing the keratin of human epidermis, nails or hair. There are 3 genera of dermatophytes causing dermatophytosis i.e., microsporum, trichophyton and epidermophyton.


Candidiasis is an infection caused by the yeast like fungus Candida albicans or occasionally other species of Candida. Clinical syndromes of candidiasis include (a) oral candidiasis (oral thrush); (b) candidiasis of the skin and genital mucous membrane; and (c) candida paronychia, which inflicts the nail.


The pharmaceutical composition of the present invention can contain an antifungal drug, which is active against dermatophytes and candida. The drug may include azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration. U.S. Pat. No. 4,352,808 discloses 3-aralkyloxy-2,3-dihydro-2-(1H-imidazolylmethyl)benzo[b]thiophene compounds having antifungal and antibacterial activity.


Steroidal Antiinflammatory Agents:


Suitable steroidal antiinflammatory agents usable in the composition of the present invention may include, although are not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone alphamethyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclarolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenalone acetonide, medrysone, amc, amcinafide, betamethasone and the balance of its esters, chloroprednisone, chloroprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylproprionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, betamethasone dipropionate, triamcinolone, and mixtures thereof may be used. The preferred steroidal antiinflammatory for use in the present invention is hydrocortisone.


Table 2 below provides a summary of currently available corticosteroid agent.









TABLE 2







List of steroidal antiinflammatory agents for topical application









Potency
Compound
Formulation





Very
Clobetasol proprionate
Cream or ointment 0.05 percent


high
Halobetasol proprionate
Cream or ointment 0.05 percent


High
Betamethasone diproprionate
Cream or ointment 0.05 percent



Betamethasone valerate
Ointment 0.1 percent



Fluocinolone acetonide
Cream 0.02 percent



Halcinonide
Cream or ointment 0.1 percent


Medium
Betamethasone valerate
Cream 0.1 percent



Fluocinolone acetonide
Cream or ointment 0.020 percent



Hydrocortisone valerate
Cream or ointment 0.2 percent



Triamcinolone acetonide
Cream, ointment, or lotion 0.1




percent or 0.020 percent


Low
Hydrocortisone
Cream, ointment, or lotion 2.5




percent or 1.0 percent









Since all corticosteroid drugs are hydrophobic, the carrier of the present invention is most suitable as a vehicle to facilitate an enhanced rate of penetration and better topical distribution thereof.


Furthermore, the intrinsic antiviral, antibacterial and antiinflammatory effects of the solidifying agents, i.e., fatty alcohols and acids, provide a combined synergetic effect that should result in a better therapeutic response to treatment.


Psoriasis is a very common chronic inflammatory skin disease, which may be the target of treatment using a composition of the present invention. Psoriasis is marked by periodic flare-ups of sharply defined red patches covered by a silvery, flaky surface.


Corticosteroid ointments, greasy preparations containing small amount of water, are commonly used for treating psoriasis. Their main disadvantage is in their stickiness, which remains for long time after treatment is over. In this respect it should be noted that the present invention exemplifies the use of a hydrocortisone containing composition that was prepared according to the teachings of the present invention (see Example 1 below). The hydrocortisone preparation was compared to a commercial composition (Example 2) and was shown be highly efficient in the treatment of psoriatic patients. Major reduction in the severity of the disease symptoms, i.e., disappearance of the silvery scales, and reduction of the oedema, erythema and pruritus were observed. Moreover the patients reported that unlike the ointments which are currently available in the market (see Table 2 above), the composition of the present invention was well distributed and absorbed into the skin, without leaving an undesirable greasiness and shiny appearance which characterized the prior art formulations.


Examples of other inflammatory diseases or disorders, which can be treated by the composition of the present invention, wherein the drug is a steroid are: seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis (gravitational eczema; varicose eczema), exfoliative dermatitis (erythroderma), lichen simplex chronicus, pemphigus, conjunctivitis and uveitis.


Topical antihistaminic preparations currently available include 1 percent and 2 percent diphenhydramine (Benadryl® and Caladryl®), 5 percent doxepin (Zonalon®) cream, phrilamine maleate, chlorpheniramine and tripelennamine, phenothiazines, promethazine hydrochloride (Phenergan®) and dimethindene maleate. These drugs, as well as additional antihistamines can also be included in the composition of the present invention.


Additionally, so-called “natural” antiinflammatory agents are useful in context of the present invention. For example, candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia cordifolia), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora mukul, may be used as an active ingredient in the composition of the present invention.


Non-Steroidal Antiinflammatory Drugs (NSAIDs):


Another preferred embodiment of the present invention is administration of non-steroidal antiinflammatory drugs (herein NSAIDs) using a composition of the present invention. NSAIDs have been used extensively in recent years for treatment of chronic rheumatic or arthritic conditions and for management of pain. The compounds are believed to bring relief by inhibiting biosynthesis of prostaglandins at affected joints or in other tissue areas. Salicylic acid, or aspirin, and ibuprofen are well-known examples of NSAIDs drugs. Patients using NSAIDs drugs administered orally face an increased risk for peptic ulcers and gastrointestinal blood loss resulting in anemia. Such adverse reactions especially plague patients taking NSAIDs drugs over prolonged periods. Administration of NSAIDs to using the carrier of the present invention will prevent gastrointestinal complications associated with the oral administration of NSAIDs. Such compositions can be used for prolonged treatment of arthritis and other diseases or disorders treated by NSAIDs drugs, while avoiding the gastrointestinal complications associated with oral dose delivery. Application of NSAIDs drugs in a topical composition to the skin of a patient allows a predetermined amount of the NSAIDs drug to be administered continuously to the patient and avoids undesirable effects present with a single or multiple administrations of larger dosages. By maintaining a sustained dosage rate, the NSAIDs drug level in the patient's blood can be better maintained within the optimal therapeutic range.


Examples of NSAIDs include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDs are fully described in the U.S. Pat. No. 4,985,459 to Sunshine et al. which is incorporated herein by reference. Examples of useful NSAIDs include acetyl salicylic acid, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, mniroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid.


Antioxidants/Radical Scavengers:


Suitable antioxidants/radical scavengers useful in context of the present invention include ascorbic acid (vitamin C) and its salts, tocopherol (vitamin E), and its derivatives such as tocopherol sorbate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the trade name Trolox®), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, the ascorbyl esters of fatty acids, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), and dihydroxy fumaric acid and its salts may be used, as well as EDTA, BHT and the like.


Antibiotics:


Antibiotics which may be used in context of the composition of the present invention, include, but are not limited to, chloramphenicol, tetracyclines, synthetic and semi-synthesic penicillins, beta-lactames, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clindamycin.


Topical Anesthetics:


Examples of topical anesthetic drugs useful in context of the composition of the present invention include benzocaine, lidocaine, bupivacaine, chloroprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.


Retinol:


Another preferred group of drugs useful in context of the composition of the present invention include retinol, all trans retinoic acid and derivatives, isomers and analogs thereof, collectively termed “retinoids”. Compositions according to the present invention, which contain retinoids as the active ingredient can be used for the treatment of acne, seborrhea, various dermatoses, inflammation of the skin, mucosal membranes, eye, vagina and the rectum, psoriasis and cancers, by application onto the affected area.


Other Drugs:


As is further detailed hereinunder, it is possible to provide the composition of the present invention onto a dermal patch to generate a transdermal delivery apparatus and applying such patch onto the skin in order to attain effective superficial treatment or enhanced penetration of a drug into the skin or through the skin.


Utilizing such a strategy, one can apply drugs which are currently administered systemically or that require transdermal delivery, in the preferred therapeutic system of the present invention. The following provides some examples for such drugs.


A broad range of analgesics may be utilized including, without limitation, morphine, codeine, heroine, methadone, thebaine, orpiarine, buprenorphine, morphinans, benzomorphans, acetaminophen, butorphanol, diflunisal, fenoprofen, fentanyl, fentanyl citrate, hydrocodone, aspirin, sodium salicylate, ibuprofen, oxymorphone, pentaxicine, naproxen, nalbuphine, mefenamic acid, meperidine and dihydroergotamine.


A typical narcotic antagonist is haloxone. Exemplary antitussive agents include, without limitation, diphenhydramine, guaifenesin, hydromorphone, ephedrine, phenylpropanolamine, theophylline, codeine, noscapine, levopropoxyphene, carbetapentane, chlorpehndianol and benzonatate.


Among the sedatives which may be utilized are, without limitation, chloral hydrate, butabarbital, alprazolam, amobarbital, chlordiazepoxide, diazepam, mephobarbital, secobarbital, diphenhydramine, ethinamate, flurazepam, halazepam, haloperidol, prochlorperazine, oxazepam, and talbutal.


Examples of cardiac drugs are, without limitation, quinidine, propranolol, nifedipine, procaine, dobutamine, digitoxin, phenyloin, sodium nitroprusside, nitroglycerin, verapamil HCl, digoxin, nicardipine HCl, and isosorbide dinitrate.


Antiemetics are illustrated by, without limitation, thiethylperazine, metoclopramide, cyclizine, meclizine, prochlorperazine, doxylamine succinate, promethazine, triflupromazine, and hydroxyzine.


A typical dopamine receptor agonist is bromocriptine mesylate. Exemplary amino acid, peptide and protein hormones include, without limitation, thyroxine, growth hormone (GH), interstitial cell stimulating hormone (ICSH), follicle-stimulating hormone (FSH), thyrotrophic hormone (TSH), adrenocorticotropic hormone (ACTH), gonadotropin releasing hormone (GnRH) such as leuprolide acetate, vasopressin and their active degradation products Some products may have sufficiently high molecular weights that absorption through the stratum corneum or mucous membranes may be difficult. Therefore, the invention is applicable only to those hormones which have molecular weights and stereo configurations which will allow passage through the skin.


Female sex hormones which can be used include, without limitations, estradiol, diethylstilbestrol, conjugated estrogens, estrone, norethindrone, medroxyprogesterone, progesterone, and norgestrel.


Typical male sex hormones which may be utilized may be represented by, without limitation, testosterone, methyltestosterone, and fluoxymesterone.


The above listed active permeants may, along with others not specifically disclosed, be used separately or in combination according to the treatment regimen desired.


Cosmetic Agents:


The carrier according to the present invention can also be used to prepare cosmetics for beauty purpose by the addition of skin care agents and perfumes.


Sun Screen Agents:


Also useful in context of the composition of the present invention are sun screening agents. A wide variety of sun screening agents are described in U.S. Pat. No. 5,087,445, to Haffey et al. U.S. Pat. No. 5,073,372, to Turner et al., U.S. Pat. No. 5,073,371, to Turner et al. and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology all of which are incorporated herein by reference in their entirety. Preferred among those sunscreens which are useful in the composition of the instant invention are those selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, octyl methoxycinnamate, 1-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomethyl salicylate, octyl salicylate, 4,4′-methoxy-t-butyldibenzoylmethane, 4-isopropyl dibenzoylmethane, 3-benzylidene camphor, 3-(4-methylbenzylidene) camphor, titanium dioxide, zinc oxide, silica, iron oxide, and mixtures thereof. Still other useful sunscreens are those disclosed in U.S. Pat. Nos. 4,937,370, to Sabatelli and 4,999,186, to Sabatelli et al. These two later references are incorporated by reference herein in their entirety. The sun screening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra-violet radiation absorption spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range. These sun screening agents provide higher efficacy, broader UV absorption, lower skin penetration and longer lasting efficacy relative to conventional sunscreens. Especially preferred examples of these sunscreens include those selected from the group consisting of 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2,4-hydroxybenzophenone, 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester with 4-hydroxydibenzoylmethane, 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone, 4-N,N-(2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane, and mixtures thereof. Generally, the sunscreens can comprise from about 0.5 percent to about 20 percent of the compositions useful herein. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF). SPF is a commonly used measure of photoprotection of a sunscreen against erythema. See Federal Register, Vol. 43, No. 166, pp. 38206-38269, Aug. 25, 1978.


Artificial Tanning Agents and Accelerators:


Examples of artificial tanning agents accelerators which can be used in context of the present invention include dihydroxyacetone, tyrosine, tyrosine esters such as ethyl tyrosinate, and phospho-DOPA.


Reducing Body Odors:


The body fluids includes eccrine sweat, apocrine sweat, sebum, build up of sensible moisture from transepidermal water loss, vaginal discharge, urine, and mixtures thereof. The body odor are odors, which are generated as a result of the natural functioning of a human body. Such odors include, but are not limited to odors produced by microorganisms of the human skin (i.e. bacterial decomposition of skin secretions), urine, or vaginal discharge, and mixtures thereof. The present invention is therefore relevant to a method of reducing body odor comprising the application of a perfume-free, odor-absorbing composition which includes the carrier of the present invention.


Antiwrinkle and Antiskin Atrophy Agents:


Examples of antiwrinkle and antiskin atrophy actives which can be used in context of the present invention include retinoic acid and its derivatives (e.g., cis and trans); salicylic acid and derivatives thereof, sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a preferred example of which is N-acetyl L-gsteine; thiols, e.g. ethane thiol; alpha-hydroxy acids, e.g. glycolic acid, and lactic acid; phytic acid, lipoic acid; lysophosphatidic acid, and skin peel agents (e.g., phenol and the like).


Excipients and Additional Agents:


The pharmaceutical or cosmetic composition of the present invention may further include a variety of pharmaceutical or cosmetic ingredients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and bestow their cosmetic acceptability. Such excipients, may be selected from the group consisting of water, surfactants, emulsifiers, diglycerides, triglycerides, stabilizing agents, antioxidants, glycerol, ethanol, propanol, isopropanol, butanol, polymeric gelling agents, flavoring, colorant and odorant agents and other formulation components, used in the art of pharmaceutical and cosmetic formulary.


Additional active and inactive ingredients may also include, without limitation, local analgesics such as benzocaine, menthol, and the like (wherein menthol is also capable of providing a soothing, cooling sensation), as well emollients, antihistamines, fragrances, thickeners and preservatives other than those already listed.


Emollients:


The compositions of the present invention can also include an emollient. Emollient is used to smooth the surface of the skin. Examples of suitable emollients include, but are not limited to, volatile and non-volatile silicone oils (e.g., dimethicone, cyclomethicone, dimethiconol, and the like), highly branched hydrocarbons, and mixtures thereof. Emollients useful in the instant invention are further described in U.S. Pat. No. 4,919,934, to Deckner et al., which is incorporated herein by reference in its entirety. The emollients can typically comprise in total from about 0.1 percent to about 25 percent, more preferably from about 0.5 percent to about 10 percent, and most preferably from about 0.5 percent to about 5 percent by weight of the composition.


A variety of additional ingredients can be incorporated into the composition of the present invention. Non-limiting examples of these additional ingredients include vitamins and derivatives thereof (e.g. tocopherol, panthenol, and the like); other thickening agents (e.g., polyacrylamide and C13-C14 isoparaffin and laureth-7, available as Sepigel 305 from Seppic Corp., Fairfield, N.J.; and branched polysaccharides such as scleroglucan available under the tradename Clearogel® CS 11 from Michel Mercier Products Inc., Mountainside, N.J.); saturated and/or unsaturated alkyl alpha hydroxy acids; resins; gums (e.g. guar gum, xanthan gum and the like); waxes (both naturally occurring and synthetic); polymers for aiding the film-forming properties and substantivity of the composition (such as a copolymer of eicosene and vinyl pyrrolidone, an example of which is available from GAF Chemical Corporation as Ganex V-220®); abrasive scrub particles for cleansing and exfoliating the skin, e.g., ACuscrub® Mild Abrasives (e.g., ACuscrub® 30, 31, 32, 40, 41, 42, 43, 44, 50, 51, and 52) available from Allied Signal, Inc., Morristown, N.J.; and 3M Brand PMU Capsules microencapsulated mineral oil available from 3M Corporation, St. Paul, Minn.; preservatives for maintaining the antimicrobial integrity of the compositions; skin penetration aids such as DMSO, 1-dodecylazacycloheptan-2-one (available as Azone® from the Upjohn Co.) and the like; skin bleaching (or lightening) agents including but not limited to hydroquinone, kojic acid and sodium metabisulfite; chelators and sequestrants; and aesthetic components such as fragrances, pigments, colorings, essential oils, skin sensates, astringents, skin soothing agents, skin healing agents and the like, nonlimiting examples of these aesthetic components include panthenol and derivatives (e.g. ethyl panthenol), aloe vera, pantothenic acid and its derivatives, clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, allantoin, bisabalol, dipotassium glycyrrhizinate and the like.


The carrier system may also comprise, when desired, a suitable gelling agent including, but not limited to, cellulose esters such as hydroxypropyl cellulose (Klucel®), hydroxyethyl cellulose (Natrosol®), polyvinylpyrrolidone (Povidone®), carboxyvinyl polymer (HIVIS105®) and the like that may be provided in any amount necessary to thicken the composition to a desired gel consistency. When formulated as a gel, the base composition exhibits favorable spreadability characteristics. In addition, it remains visible on the skin surface longer, thereby instilling in the user the impression that the vehicle is more completely delivering its active ingredient(s).


In addition to the aforementioned ingredients, it should also be noted that the following ingredients may also be included in the inventive composition, as desired: coloring agents, fragrances, conditioners, moisturizers, surfactants, antioxidants, preservatives, etc.


Preferred ingredients are saturated and/or unsaturated alkyl alpha hydroxy acids, at a level of from about 0.05 percent to about 5 percent by weight of the composition, such as lactic acid, lactate salts (e.g., ammonium and quaternary alyl ammonium), glycolic acid, glycolate salts (e.g., ammonium and quaternary allyl ammonium), and fruit acids. A discussion of alpha hydroxy acids is disclosed in Walter P. Smith, Hydroxy Acids and Skin Aging, Soap/Cosmetics/Chemical Specialties. pp. 54-59, (September 1993), which is herein incorporated by reference in its entirety.


Preservatives:


Antimicrobial preservatives useful in the present invention include biocidal and biostatic compounds (substances that kill microorganisms and/or regulate the growth of microorganisms). Suitable antimicrobial preservatives have a solubility of 0.3 percent or greater. In addition, suitable preservatives are those which can come into contact with skin without high irritation potential. Preservatives suitable for use in the present compositions are described in U.S. Pat. No. 5,534,165, to Pilosof et al.


It is preferable to use a broad spectrum preservative such as one that is effective both on bacteria (both gram positive and gram negative) and fungi. A limited spectrum preservative such as one that is only effective on a single group of microorganisms, for example fungi, can be used in combination with a broad spectrum preservative or other limited spectrum preservatives with complimentary and/or supplementary activity. A mixture of broad spectrum preservatives can also be used.


Colorants and Dyes:


Colorants and dyes can be optionally added to the odor absorbing compositions for visual appeal and performance impression. When colorants are used, care must be taken in the selection of choosing dyes that will not color skin. Preferred colorants for use in the present compositions are highly water-soluble dyes, e.g., acid blue 3, acid blue 104, acid green 1, acid green 25, acid yellow 3, acid yellow 73 sodium salt, D&C green No. 5, 6 & 8, D&C yellow No. 7, 8, 10 & 11, D&C violet No. 2, FD&C blue No. 1 & 2, FD&C green No. 3, FD&C yellow No. 5 & 6, and mixtures thereof.


Other Optional Ingredients:


The composition of the present invention can optionally contain adjunct odor-controlling materials, such as zinc salts, cationic polymers, anionic polymers, carbonate salts, bicarbonate salts, zeolites, and activated carbon; chelating agents; colorants; and/or antiperspirants.


Optionally, the composition of the present invention can include zinc salts for added odor absorption and/or antimicrobial benefit for the cyclodextrin solution. Zinc compounds have been used most often for their ability to ameliorate malodor, e.g., in mouth wash products, as disclosed in U.S. Pat. Nos. 4,325,939 and 4,469,674 to Shah, et al. Highly-ionized zinc salts, such as zinc chloride, provide the best source of zinc ions. The zinc salt, zinc phenolsulfonate, is preferred for use in the skin composition of the present invention; although others may also fall within the scope of the present invention. However, care must be taken in selecting zinc salts, as well as their levels, since some may be irritants to the skin and they are not preferred for use in the present invention.


Administration Via Dermal Patch:


The compositions of the present invention may also be delivered to the skin using conventional dermal-type patches or articles, wherein the active ingredients composition is contained within a laminated structure, that serves as a drug delivery device to be affixed to the skin. In such a structure, the active ingredients composition is contained in a layer, or “reservoir”, underlying an upper backing layer. The laminated structure may contain a single reservoir, or it may contain multiple reservoirs. In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during active ingredients delivery. Examples of suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like. The particular polymeric adhesive selected will depend on the particular active ingredients, vehicle, etc., i.e., the adhesive must be compatible with all components of the active ingredients-containing composition. Alternatively, the active ingredients-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.


The backing layer in these laminates, which serves as the upper surface of the device, functions as the primary structural element of the laminated structure and provides the device with much of its flexibility. The material selected for the backing material should be selected so that it is substantially impermeable to the active ingredients and to any other components of the active ingredients-containing composition, thus preventing loss of any components through the upper surface of the device. The backing layer may be either occlusive or nonocclusive, depending on whether it is desired that the skin become hydrated during active ingredients delivery. The backing is preferably made of a sheet or film of a preferably flexible elastomeric material. Examples of polymers that are suitable for the backing layer include polyethylene, polypropylene, and polyesters.


During storage and prior to use, the laminated structure includes a release liner. Immediately prior to use, this layer is removed from the device to expose the basal surface thereof, either the active ingredients reservoir or a separate contact adhesive layer, so that the system may be affixed to the skin. The release liner should be made from a active ingredients/vehicle impermeable material.


Such devices may be fabricated using conventional techniques, known in the art, for example by casting a fluid admixture of adhesive, active ingredients and vehicle onto the backing layer, followed by lamination of the release liner. Similarly, the adhesive mixture may be cast onto the release liner, followed by lamination of the backing layer. Alternatively, the active ingredients reservoir may be prepared in the absence of active ingredients or excipient, and then loaded by “soaking” in a active ingredients/vehicle mixture.


Therapeutic Effect and Dosage:


The therapeutic efficacy of the compositions described herein can be determined by standard pharmaceutical procedures in experimental animal models or human beings. The data obtained from these studies can be used in formulating a range of dosage for use in human (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1).


The effective concentration of the drug is calculated by procedures known in the art that can be employed to determine the effective local concentration. For example, corticosteroid induced vasoconstriction in man may provide a preliminary useful hint to topical antiinflammatory activity.


The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.


Short term studies over one or two weeks may not be the only relevant investigation for the clinical comparison of the topical drugs. In practice these are sometimes applied over long periods of time and the differences may be apparent only after months of treatment. For this reason, depending on the novelty of the product and the indications claimed, certain studies of efficacy as well as of safety will be required.


Since the hydrophobic agent can be derived from a biological source, it is necessary to assess the repeatability of the therapeutic effect as well as the reproducibility, the specificity and the accuracy of the agent. This should be done by an analytical chemistry laboratory which is defined as GLP (Good Laboratory Practice).


Compositions of the present invention may, if desired, be presented in a bottle or jar or other container approved by the FDA, which may contain one or more unit dosage forms containing the active ingredient. Compositions such as those described in the present invention may be particularly susceptible to microbial and other contamination, and special measures need to be taken to prevent any contamination. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment for acne or for psoriasis and the like.


The gist and advantages of the present invention over the prior art:


The gist of the present invention is based on the striking discovery that the addition of fatty alcohols to hydrophobic liquids, such as saturated, mono-unsaturated or poly-unsaturated oils, as well as mineral and silicone oils, may alter the physicochemical properties of the material, including the solidification thereof. This appears to be particularly relevant when the fatty alcohol has a molecular weight greater than 200 Da and at least one hydroxyl group in its chemical structure. The addition of a fatty alcohol to a liquid oil also gives rise to thixotropic properties (e.g., being semi-solid at rest and liquid upon application of shear forces thereto). This property enables application of a thixotropic mixture as a semi-solid state to a body surface, which subsequently becomes substantially liquid and therefore more spreadable and penetrable when rubbed onto the body surface. Thus, one of the most important properties of the carrier and composition of the present invention is that they are semi-solid at rest and that they liquefy upon application of shear forces thereto. Semi-solid hydrophobic formulations are important not only for the pharmaceutical market but also for cosmetic products, such as carriers of sunscreen compounds, oil-soluble plant extracts, materials for scrubbing purposes and other active and non-active cosmetic ingredients. Unlike aqueous liquids, which are rather easy to solidify due to their hydrogen bond forming ability, oils are difficult to solidify. Several methods have been proposed to increase the viscosity of oils. Various gelling agent, such as inorganic complexing agents (U.S. Pat. No. 4,780,309), hydrocolloids (U.S. Pat. No. 4,576,645), polymers and copolymers (U.S. Pat. Nos. 5,985,821; 5,925,707), polysaccharides (U.S. Pat. No. 5,961,998) have been previously described in the context of solidifying oils for use in food and cosmetics. The use of waxes, fatty alcohols, fatty acids and 12 hydroxy stearic acid in solidifying waste oils, in order to facilitate the removal of such oils have also been described (JP-A-112385/1979; JP-A-106298/1980). U.S. Pat. No. 5,817,322 teaches pharmaceutical compositions, comprising an oil and beeswax as a gelling agent, which form a netted framework of the beeswax and form a film after application on a body surface.


However, the prior art fails to teach a carrier or composition for topical application which is semi-solid at rest and which liquefies upon application of shear forces thereto.


EXAMPLES

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.


Example 1
Preparation of a Corticosteroid Composition

Stearyl alcohol (60 grams) was heated to 80° C. USP olive oil (940 grams) was heated to the same temperature. While at 80° C., the stearyl alcohol was added to the preheated olive oil. 20 grams glycerin, 20 grams tri-stearin, 1 gram of an antioxidant mixture were added by agitation. 1 gram of betamethasone valerate was added and the mixture was poured into containers (5 gram tubes) and was allowed to cool spontaneously. While the mixture cooled to ambient temperature it gradually turned into a semi-solid.


Example 2
Efficacy of the Corticosteroid Composition for the Treatment of Psoriasis

In a preliminary experiment, five patients with psoriasis were treated with the corticosteroid preparation described in Example 1, twice a day, for 10 days. In three out of five patients the psoriatic plaques and skin thickness were significantly reduced after 7-10 days of treatment (FIG. 1). The forth patient had a moderate improvement and fifth showed only mild response to the treatment.


Example 3
A Double Blind Comparative Study Between the Corticosteroid Composition and a Conventional Ointment

Eight subjects were requested to apply 1 gram of the corticosteroid composition described in Example 1 on one arm and 1 gram of commercial betamethasone valerate ointment, on the other arm. The study was performed in a double blind manner. The subjects had to describe their opinion about the ease of application, ease of spreading, spreadability and penetrability of each of the products and to give their scores on a scale of 0 to 3 (0=poor; 1=barely acceptable; 2=acceptable and 3=excellent).


As can be clearly seen in Table 3 below, the corticosteroid composition of Example 1 obtained higher score in each of the study parameters.









TABLE 3







Comparison between the corticosteroid composition


and Betamethasone commercial ointment












Corticosteroid
Commercial




Composition
Betamethasone




(Example 1)
valerate ointment



Parameters
mean Score
mean Score







Ease of application
2.5
1.8



Ease of spreading
2.4
1.8



Spreadability
2.8
1.6



Penetrability
2.4
2.0



Lack of stickiness
2.6
1.0



Lack of greasiness
2.6
0.8



Lack of shiny look
1.9
1.4



Overall rating
2.6
1.6










Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

Claims
  • 1. An oleaginous pharmaceutical carrier comprising: a mixture comprising, by weight:75-99 percent of a hydrophobic solvent, and1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone, and (iii) a mixture thereofwherein the pharmaceutical carrier is semi-solid at rest and liquefies upon application of shear forces thereto; andwherein the carrier is free of a netted framework of solidifying agent.
  • 2. A pharmaceutical composition, comprising the carrier of claim 1, further comprising a therapeutically effective amount of a biologically active substance.
  • 3. The pharmaceutical composition of claim 2, wherein the biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.
  • 4. The pharmaceutical composition of claim 3, wherein the antibiotic agent comprises a tetracycline antibiotic.
  • 5. The pharmaceutical composition of claim 2, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba oil.
  • 6. The pharmaceutical composition of claim 2, wherein said hydrophobic solvent includes an oil selected from the group consisting of marine animal derived oils, terrestrial animal derived oils, mineral oils, silicone oils and plant-derived oils.
  • 7. The pharmaceutical composition of claim 2, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.
  • 8. The pharmaceutical composition of claim 2, wherein the hydrophobic solvent comprises a silicone oil.
  • 9. The pharmaceutical composition of claim 2, wherein the carrier provides a protective moisture barrier.
  • 10. The pharmaceutical composition of claim 2, wherein the composition spreads easily and is non sticky.
  • 11. The pharmaceutical composition of claim 2, wherein said solidifying agent includes a 12-hydroxy fatty acid and or behenyl alcohol.
  • 12. The pharmaceutical composition of claim 2, wherein the solidifying agent is solid at ambient temperature; andwherein the biologically active substance comprises a tetracycline antibiotic in a therapeutically effective amount to treat a disease or disorder of the skin or mucosal membrane.
  • 13. A method of applying: a pharmaceutical composition to a skin or a mucosal membrane having a disease or disorder, comprising topically administering the pharmaceutical composition to the skin or the mucosal membrane surface, said pharmaceutical composition comprising, by weight, a mixture of:75-99 percent of a hydrophobic solvent,1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone and (iii) a mixture thereof; anda biologically active agent,wherein the composition is semi-solid at rest and liquefies upon application of shear forces thereto; andwherein the composition is free of a netted framework of solidifying agent.
  • 14. The method of claim 13, wherein on application the composition freely spreads on the skin surface or mucosal membrane and is rapidly absorbed.
  • 15. The method of claim 14, wherein the composition spreads without film formation.
  • 16. The method of claim 13, wherein the composition is adapted to facilitate enhanced penetration of the active agent.
  • 17. The method of claim 13, wherein the disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.
  • 18. The method of claim 13, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritic agent and a scabicide agent.
  • 19. The method of claim 13, wherein the biologically active agent comprises a tetracycline antibiotic.
  • 20. The method of claim 13, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba oil.
  • 21. The method of claim 13, wherein said hydrophobic solvent includes an oil selected from the group consisting of marine animal derived oils, terrestrial animal derived oils, mineral oils, silicone oils and plant-derived oils.
  • 22. The method of claim 13, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.
  • 23. The method of claim 13, wherein the composition provides a protective moisture barrier.
  • 24. The method of claim 15, wherein the composition is delivered by means of a dermal patch or as a suppository.
  • 25. The method of claim 13, wherein said solidifying agent includes a 12-hydroxy fatty acid and or behenyl alcohol.
  • 26. The method of claim 13, wherein the solidifying agent is solid at ambient temperature; wherein the biologically active substance comprises a tetracycline antibiotic in a therapeutically effective amount to treat a disease or disorder of the skin or mucosal membrane.
  • 27. A method of preparing an oleaginous pharmaceutical carrier, the method comprising the steps of mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of the solidifying agent so as to obtain a mixture containing 75-99 percent of the hydrophobic solvent by weight and 1-25 percent of the solidifying agent by weight; and cooling the mixture, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone, and (iii) a mixture thereof; andwherein the pharmaceutical carrier is semi-solid at rest and liquefies upon application of shear forces thereto.
  • 28. The method of claim 27, further comprising: mixing into the mixture a therapeutically or cosmetically effective amount of a biologically active substance.
  • 29. The method of claim 18, wherein the antibiotic agent is selected from the group consisting of chloramphenicol, a tetracyclines, a synthetic penicillins, a semi-synthetic penicillin, a beta-lactam, a quinolone, a fluoroquinolone, a macrolide antibiotic, a peptide antibiotic, a cyclosporine, erythromycin clyndamycin and mixtures thereof.
  • 30. The pharmaceutical composition of claim 2, wherein the biologically active substance is selected from the group consisting of chloramphenicol, a tetracyclines, a synthetic penicillin, semi-synthetic penicillins, a beta-lactam, a quinolone, a fluoroquinolone, a macrolide antibiotic, a peptide antibiotic, a cyclosporine, erythromycin, clyndamycin and mixtures thereof.
  • 31. A method of treating a disease or disorder of a skin or a mucosal membrane comprising: topically administering a pharmaceutical composition to the skin or the mucosal membrane, said pharmaceutical composition comprising, by weight, a mixture of:75-99 percent of a hydrophobic solvent,1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting of (i) at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone (ii) at least one fatty acid having at least 18 carbons in its carbon backbone and (iii) a mixture thereof; anda biologically active agent selected from the group consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent, and a scabicide agent and wherein the antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin, clyndamycin, and mixtures thereof;wherein the composition is semi-solid at rest and liquefies upon application of shear forces thereto;wherein the composition is free of a netted framework of solidifying agent; andwherein the disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia, excessive hair growth, ichthyosis, infection, inflammation, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis, and exfoliative dermatitis.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation under 35 U.S.C. §120 of U.S. patent application Ser. No. 11/294,318, filed Dec. 5, 2005, which is a continuation of U.S. patent application Ser. No. 10/392,071, filed on Mar. 19, 2003, now U.S. Pat. No. 6,994,863, which is a divisional of U.S. patent application Ser. No. 09/653,267, filed on Aug. 31, 2000, now U.S. Pat. No. 6,967,023, which is a non-provisional of U.S. Provisional Patent Application No. 60/216,162, filed Jul. 3, 2000, all of which applications are hereby incorporated by reference.

US Referenced Citations (771)
Number Name Date Kind
1159250 Moulton Nov 1915 A
1666684 Carstens Apr 1928 A
1924972 Beckert Aug 1933 A
2085733 Bird Jul 1937 A
2390921 Clark Dec 1945 A
2524590 Boe Oct 1950 A
2586287 Apperson Feb 1952 A
2617754 Neely Nov 1952 A
2767712 Waterman Oct 1956 A
2968628 Reed Jan 1961 A
3004894 Johnson et al. Oct 1961 A
3062715 Reese et al. Nov 1962 A
3067784 Gorman Dec 1962 A
3092255 Hohman Jun 1963 A
3092555 Horn Jun 1963 A
3141821 Compeau Jul 1964 A
3142420 Gawthrop Jul 1964 A
3144386 Brightenback Aug 1964 A
3149543 Naab Sep 1964 A
3154075 Weckesser Oct 1964 A
3178352 Erickson Apr 1965 A
3236457 Kennedy et al. Feb 1966 A
3244589 Sunnen Apr 1966 A
3252859 Silver May 1966 A
3261695 Sienkiewicz Jul 1966 A
3263867 Lehmann Aug 1966 A
3263869 Corsette Aug 1966 A
3298919 Bishop et al. Jan 1967 A
3301444 Wittke Jan 1967 A
3303970 Breslau et al. Feb 1967 A
3330730 Hernandez Jul 1967 A
3333333 Noack Aug 1967 A
3346451 Collins et al. Oct 1967 A
3366494 Bower et al. Jan 1968 A
3369034 Chalmers Feb 1968 A
3377004 Wittke Apr 1968 A
3384541 Clark et al. May 1968 A
3395214 Mummert Jul 1968 A
3395215 Schubert Jul 1968 A
3401849 Weber, III Sep 1968 A
3419658 Sanders Dec 1968 A
3456052 Gordon Jul 1969 A
3527559 Sliwinski Sep 1970 A
3540448 Sunnen Nov 1970 A
3559890 Brooks et al. Feb 1971 A
3561262 Borucki Feb 1971 A
3563098 Weber, III Feb 1971 A
3574821 Pfirrmann Apr 1971 A
3577518 Shepherd May 1971 A
3667461 Zamarra Jun 1972 A
3751562 Nichols Aug 1973 A
3770648 Mackles Nov 1973 A
3787566 Gauvreau Jan 1974 A
3819524 Schubert et al. Jun 1974 A
3841525 Siegel Oct 1974 A
3849580 Weinstein et al. Nov 1974 A
3865275 De Nunzio Feb 1975 A
3866800 Schmitt Feb 1975 A
3882228 Boncey et al. May 1975 A
3886084 Vassiliades May 1975 A
3890305 Weber et al. Jun 1975 A
3912665 Spitzer et al. Oct 1975 A
3923970 Breuer Dec 1975 A
3929985 Webb, Jr. Dec 1975 A
3952916 Phillips Apr 1976 A
3959160 Horsler et al. May 1976 A
3962150 Viola Jun 1976 A
3963833 DeSalva et al. Jun 1976 A
3966090 Prussin et al. Jun 1976 A
3966632 Colliopoulos et al. Jun 1976 A
3970219 Spitzer et al. Jul 1976 A
3970584 Hart et al. Jul 1976 A
3993224 Harrison Nov 1976 A
3997467 Jederstrom Dec 1976 A
4001391 Feinstone et al. Jan 1977 A
4001442 Stahlberger et al. Jan 1977 A
4018396 Showmaker et al. Apr 1977 A
4019657 Spitzer et al. Apr 1977 A
4083974 Turi Apr 1978 A
4102995 Hebborn Jul 1978 A
4110426 Barnhurst et al. Aug 1978 A
4124149 Spitzer et al. Nov 1978 A
4145411 Mende Mar 1979 A
4151272 Geary et al. Apr 1979 A
4160827 Cho et al. Jul 1979 A
4213979 Levine Jul 1980 A
4214000 Papa Jul 1980 A
4226344 Booth et al. Oct 1980 A
4229432 Geria Oct 1980 A
4230701 Holick et al. Oct 1980 A
4241048 Durbak et al. Dec 1980 A
4241149 Labes et al. Dec 1980 A
4252787 Sherman et al. Feb 1981 A
4254104 Suzuki et al. Mar 1981 A
4268499 Keil May 1981 A
4271149 Winicov et al. Jun 1981 A
4292250 DeLuca et al. Sep 1981 A
4292326 Nazzaro-Porro et al. Sep 1981 A
4299826 Luedders Nov 1981 A
4305936 Klein Dec 1981 A
4309995 Sacco Jan 1982 A
4310510 Sherman et al. Jan 1982 A
4323694 Scala, Jr. Apr 1982 A
4325939 Shah Apr 1982 A
4329990 Sneider May 1982 A
4335120 Holick et al. Jun 1982 A
4352808 Rane et al. Oct 1982 A
4385161 Caunt et al. May 1983 A
4386104 Nazzaro-Porro May 1983 A
4393066 Garrett et al. Jul 1983 A
4427670 Ofuchi et al. Jan 1984 A
4439416 Cordon et al. Mar 1984 A
4439441 Hallesy et al. Mar 1984 A
4440320 Wernicke Apr 1984 A
4447486 Hoppe et al. May 1984 A
4469674 Shah et al. Sep 1984 A
4508705 Chaudhuri et al. Apr 1985 A
4522948 Walker Jun 1985 A
4529601 Broberg et al. Jul 1985 A
4529605 Lynch et al. Jul 1985 A
4552872 Cooper et al. Nov 1985 A
4574052 Gupte et al. Mar 1986 A
4576961 Lorck et al. Mar 1986 A
4595526 Lai Jun 1986 A
4603812 Stoesser et al. Aug 1986 A
4627973 Moran et al. Dec 1986 A
4628063 Haines et al. Dec 1986 A
4661524 Thomson et al. Apr 1987 A
4672078 Sakai et al. Jun 1987 A
4673569 Shernov et al. Jun 1987 A
4678463 Millar Jul 1987 A
4701320 Hasegawa et al. Oct 1987 A
4725609 Kull, Jr. et al. Feb 1988 A
4738396 Doi et al. Apr 1988 A
4741855 Grote et al. May 1988 A
4752465 Mackles Jun 1988 A
4770634 Pellico Sep 1988 A
4780309 Geria et al. Oct 1988 A
4784842 London et al. Nov 1988 A
4792062 Goncalves Dec 1988 A
4798682 Ansmann Jan 1989 A
4804674 Curtis-Prior et al. Feb 1989 A
4806262 Snyder Feb 1989 A
4808388 Beutler et al. Feb 1989 A
4822613 Rodero Apr 1989 A
4822614 Rodero Apr 1989 A
4826048 Skorka et al. May 1989 A
4827378 Gillan et al. May 1989 A
4828837 Uster et al. May 1989 A
4836217 Fischer et al. Jun 1989 A
4837019 Georgalas et al. Jun 1989 A
4837378 Borgman Jun 1989 A
4844902 Grohe Jul 1989 A
4847068 Dole et al. Jul 1989 A
4849117 Bronner et al. Jul 1989 A
4855294 Patel et al. Aug 1989 A
4863900 Pollock et al. Sep 1989 A
4867967 Crutcher Sep 1989 A
4873078 Edmundson et al. Oct 1989 A
4874794 Katz Oct 1989 A
4877805 Kligman Oct 1989 A
4885282 Thornfeldt Dec 1989 A
4897262 Nandagiri et al. Jan 1990 A
4902281 Avoy Feb 1990 A
4906453 Tsoucalas Mar 1990 A
4913893 Varco et al. Apr 1990 A
4919934 Deckner et al. Apr 1990 A
4954487 Cooper et al. Sep 1990 A
4956049 Bernheim et al. Sep 1990 A
4957732 Grollier et al. Sep 1990 A
4963351 Weston Oct 1990 A
4966779 Kirk Oct 1990 A
4970067 Panandiker et al. Nov 1990 A
4975466 Bottcher et al. Dec 1990 A
4981367 Brazelton Jan 1991 A
4981677 Thau Jan 1991 A
4981679 Briggs et al. Jan 1991 A
4981845 Pereira Jan 1991 A
4985459 Sunshine et al. Jan 1991 A
4992478 Geria Feb 1991 A
4993496 Riedle et al. Feb 1991 A
5002540 Brodman et al. Mar 1991 A
5002680 Schmidt et al. Mar 1991 A
5007556 Lover Apr 1991 A
5013297 Cattanach May 1991 A
5015471 Birtwistle et al. May 1991 A
5019375 Tanner et al. May 1991 A
5034220 Helioff et al. Jul 1991 A
5035895 Shibusawa et al. Jul 1991 A
5053228 Mori et al. Oct 1991 A
5071648 Rosenblatt Dec 1991 A
5071881 Parfondry et al. Dec 1991 A
5073371 Turner et al. Dec 1991 A
5082651 Healey et al. Jan 1992 A
5087618 Bodor Feb 1992 A
5089252 Grollier et al. Feb 1992 A
5091111 Neumiller Feb 1992 A
5094853 Hagarty Mar 1992 A
5100917 Flynn et al. Mar 1992 A
5104645 Cardin et al. Apr 1992 A
5112359 Murphy et al. May 1992 A
5114718 Damani May 1992 A
5122519 Ritter Jun 1992 A
5130121 Kopolow et al. Jul 1992 A
5133972 Ferrini et al. Jul 1992 A
5135915 Czarniecki et al. Aug 1992 A
5137714 Scott Aug 1992 A
5143717 Davis Sep 1992 A
5156765 Smrt Oct 1992 A
5164357 Bartman et al. Nov 1992 A
5164367 Pickart Nov 1992 A
5167950 Lins Dec 1992 A
5171577 Griat et al. Dec 1992 A
5196405 Packman Mar 1993 A
5204093 Victor Apr 1993 A
5208031 Kelly May 1993 A
5217707 Szabo et al. Jun 1993 A
5219877 Shah et al. Jun 1993 A
5221696 Ke et al. Jun 1993 A
5230897 Griffin et al. Jul 1993 A
5236707 Stewart, II Aug 1993 A
5252246 Ding et al. Oct 1993 A
5254334 Ramirez et al. Oct 1993 A
5262407 Leveque et al. Nov 1993 A
5266592 Grub et al. Nov 1993 A
5279819 Hayes Jan 1994 A
5286475 Louvet et al. Feb 1994 A
5300286 Gee Apr 1994 A
5301841 Fuchs Apr 1994 A
5308643 Osipow et al. May 1994 A
5314904 Egidio et al. May 1994 A
5322683 Mackles et al. Jun 1994 A
5326557 Glover et al. Jul 1994 A
5344051 Brown Sep 1994 A
5346135 Vincent Sep 1994 A
5352437 Nakagawa et al. Oct 1994 A
5369131 Poli et al. Nov 1994 A
5378451 Gorman et al. Jan 1995 A
5378730 Lee et al. Jan 1995 A
5380761 Szabo Anna Z. et al. Jan 1995 A
5384308 Henkin Jan 1995 A
5385943 Nazzaro-Porro Jan 1995 A
5389676 Michaels Feb 1995 A
5397312 Rademaker et al. Mar 1995 A
5398846 Corba et al. Mar 1995 A
5399205 Shinohara et al. Mar 1995 A
5411992 Eini et al. May 1995 A
5422361 Munayyer et al. Jun 1995 A
5429815 Faryniarz et al. Jul 1995 A
5435996 Glover et al. Jul 1995 A
5447725 Damani et al. Sep 1995 A
5449520 Frigerio et al. Sep 1995 A
5451404 Furman Sep 1995 A
5482965 Rajadhyaksha Jan 1996 A
5491245 Gruning et al. Feb 1996 A
5500211 George et al. Mar 1996 A
5508033 Briand Apr 1996 A
5512555 Waldstreicher Apr 1996 A
5514367 Lentini et al. May 1996 A
5514369 Salka et al. May 1996 A
5520918 Smith May 1996 A
5523078 Baylin Jun 1996 A
5527534 Myhling Jun 1996 A
5527822 Scheiner Jun 1996 A
5529770 McKinzie et al. Jun 1996 A
5531703 Skwarek et al. Jul 1996 A
5534261 Rodgers et al. Jul 1996 A
5536743 Borgman Jul 1996 A
5540853 Trinh et al. Jul 1996 A
5545401 Shanbrom Aug 1996 A
5567420 McEleney et al. Oct 1996 A
5576016 Amselem et al. Nov 1996 A
5578315 Chien et al. Nov 1996 A
5585104 Ha et al. Dec 1996 A
5589157 Hatfield Dec 1996 A
5589515 Suzuki et al. Dec 1996 A
5597560 Bergamini et al. Jan 1997 A
5603940 Candau et al. Feb 1997 A
5605679 Hansenne et al. Feb 1997 A
5608119 Amano et al. Mar 1997 A
5611463 Favre Mar 1997 A
5612056 Jenner et al. Mar 1997 A
5613583 Kono et al. Mar 1997 A
5613623 Hildebrandt Mar 1997 A
5614171 Clavenna et al. Mar 1997 A
5614178 Bloom et al. Mar 1997 A
5635469 Fowler et al. Jun 1997 A
5641480 Vermeer Jun 1997 A
5643600 Mathur Jul 1997 A
5645842 Gruning et al. Jul 1997 A
5650554 Moloney Jul 1997 A
5658575 Ribier et al. Aug 1997 A
5658749 Thornton Aug 1997 A
5658956 Martin et al. Aug 1997 A
5663208 Martin Sep 1997 A
5672634 Tseng et al. Sep 1997 A
5679324 Lisboa et al. Oct 1997 A
5683710 Akemi et al. Nov 1997 A
5686088 Mitra et al. Nov 1997 A
5693258 Tonomura et al. Dec 1997 A
5695551 Buckingham et al. Dec 1997 A
5700396 Suzuki et al. Dec 1997 A
5716611 Oshlack et al. Feb 1998 A
5716621 Bello Feb 1998 A
5719122 Chiodini et al. Feb 1998 A
5719197 Kanios et al. Feb 1998 A
5725872 Stamm et al. Mar 1998 A
5725874 Oda Mar 1998 A
5730964 Waldstreicher Mar 1998 A
5733558 Breton et al. Mar 1998 A
5733572 Unger et al. Mar 1998 A
5747049 Tominaga May 1998 A
5753241 Ribier et al. May 1998 A
5753245 Fowler et al. May 1998 A
5759520 Sachetto Jun 1998 A
5759579 Singh et al. Jun 1998 A
5767104 Bar-Shalom et al. Jun 1998 A
5773410 Yamamoto Jun 1998 A
5783202 Tomlinson et al. Jul 1998 A
5788664 Scalise Aug 1998 A
5792448 Dubief et al. Aug 1998 A
5792922 Moloney et al. Aug 1998 A
5797955 Walters Aug 1998 A
5804546 Hall et al. Sep 1998 A
5817322 Xu Oct 1998 A
5824650 De Lacharriere et al. Oct 1998 A
5833960 Gers-Barlag et al. Nov 1998 A
5833961 Siegfried et al. Nov 1998 A
5837270 Burgess Nov 1998 A
5840744 Borgman Nov 1998 A
5840771 Oldham et al. Nov 1998 A
5843411 Hernandez et al. Dec 1998 A
5846983 Sandborn et al. Dec 1998 A
5849042 Lim et al. Dec 1998 A
5856452 Moloney et al. Jan 1999 A
5858371 Singh et al. Jan 1999 A
5865347 Welschoff Feb 1999 A
5866040 Nakama et al. Feb 1999 A
5869529 Sintov et al. Feb 1999 A
5871720 Gutierrez et al. Feb 1999 A
5877216 Place et al. Mar 1999 A
5879469 Avram et al. Mar 1999 A
5881493 Restive Mar 1999 A
5885581 Massand Mar 1999 A
5889028 Sandborn et al. Mar 1999 A
5889054 Yu et al. Mar 1999 A
5891458 Britton et al. Apr 1999 A
5902574 Stoner et al. May 1999 A
5902789 Stoltz May 1999 A
5905092 Osborne et al. May 1999 A
5910382 Goodenough et al. Jun 1999 A
5911981 Dahms et al. Jun 1999 A
5912007 Pan et al. Jun 1999 A
5914122 Otterbeck et al. Jun 1999 A
5914310 Li et al. Jun 1999 A
5922331 Mausner Jul 1999 A
5925669 Katz et al. Jul 1999 A
5948682 Moloney Sep 1999 A
5951544 Konwitz Sep 1999 A
5951989 Heymann Sep 1999 A
5951993 Scholz et al. Sep 1999 A
5952373 Lanzendorfer et al. Sep 1999 A
5952392 Katz et al. Sep 1999 A
5955414 Brown et al. Sep 1999 A
5959161 Kenmochi et al. Sep 1999 A
5961957 McAnalley Oct 1999 A
5961998 Arnaud et al. Oct 1999 A
5972310 Sachetto Oct 1999 A
5976555 Liu et al. Nov 1999 A
5980904 Leverett et al. Nov 1999 A
5990100 Rosenberg et al. Nov 1999 A
5993846 Friedman et al. Nov 1999 A
6001341 Genova et al. Dec 1999 A
6006948 Auer Dec 1999 A
6019967 Breton et al. Feb 2000 A
6024942 Tanner et al. Feb 2000 A
6030630 Fleury et al. Feb 2000 A
6033647 Touzan et al. Mar 2000 A
6039936 Restle et al. Mar 2000 A
6042848 Lawyer et al. Mar 2000 A
6045779 Mueller et al. Apr 2000 A
6071536 Suzuki et al. Jun 2000 A
6075056 Quigley, Jr. et al. Jun 2000 A
6080394 Lin et al. Jun 2000 A
6087317 Gee Jul 2000 A
6090772 Kaiser et al. Jul 2000 A
6093408 Hasenoehrl et al. Jul 2000 A
6096756 Crain et al. Aug 2000 A
6110477 Hernandez et al. Aug 2000 A
6110966 Pollock Aug 2000 A
6113888 Castro et al. Sep 2000 A
6116466 Gueret Sep 2000 A
6121210 Taylor Sep 2000 A
6126920 Jones et al. Oct 2000 A
6140355 Egidio et al. Oct 2000 A
6146645 Deckers et al. Nov 2000 A
6146664 Siddiqui Nov 2000 A
6162834 Sebillotte-Arnaud et al. Dec 2000 A
6165455 Torgerson et al. Dec 2000 A
6168576 Reynolds Jan 2001 B1
6171347 Kunz et al. Jan 2001 B1
6180669 Tamarkin Jan 2001 B1
6183762 Deckers et al. Feb 2001 B1
6186367 Harrold Feb 2001 B1
6187290 Gilchrist et al. Feb 2001 B1
6189810 Nerushai et al. Feb 2001 B1
6190365 Abbott et al. Feb 2001 B1
6204285 Fabiano et al. Mar 2001 B1
6210656 Touzan et al. Apr 2001 B1
6210742 Deckers et al. Apr 2001 B1
6214318 Osipow et al. Apr 2001 B1
6214788 Velazco et al. Apr 2001 B1
6221381 Shelford et al. Apr 2001 B1
6221823 Crisanti et al. Apr 2001 B1
6224888 Vatter et al. May 2001 B1
6231837 Stroud et al. May 2001 B1
6232315 Shafer et al. May 2001 B1
6251369 Stoltz Jun 2001 B1
6258374 Friess et al. Jul 2001 B1
6271295 Powell et al. Aug 2001 B1
6274150 Simonnet et al. Aug 2001 B1
6287546 Reich et al. Sep 2001 B1
6294550 Place et al. Sep 2001 B1
6229032 Hamilton Oct 2001 B1
6299023 Arnone Oct 2001 B1
6299900 Reed et al. Oct 2001 B1
6305578 Hildebrandt et al. Oct 2001 B1
6306841 Place et al. Oct 2001 B1
6308863 Harman Oct 2001 B1
6319913 Mak et al. Nov 2001 B1
6328950 Franzke et al. Dec 2001 B1
6328982 Shiroyama et al. Dec 2001 B1
6333362 Lorant Dec 2001 B1
6335022 Simonnet et al. Jan 2002 B1
6341717 Auer Jan 2002 B2
6344218 Dodd et al. Feb 2002 B1
6348229 Eini et al. Feb 2002 B1
6358541 Goodman Mar 2002 B1
6364854 Ferrer et al. Apr 2002 B1
6372234 Deckers et al. Apr 2002 B1
6375960 Simonnet et al. Apr 2002 B1
6382982 Wilcox et al. May 2002 B1
6383471 Chen et al. May 2002 B1
6395258 Steer May 2002 B1
6395300 Straub et al. May 2002 B1
6403061 Candau et al. Jun 2002 B1
6403069 Chopra et al. Jun 2002 B1
6410036 De Rosa et al. Jun 2002 B1
6423323 Neubourg Jul 2002 B2
6428772 Singh et al. Aug 2002 B1
6433003 Bobrove et al. Aug 2002 B1
6433024 Popp et al. Aug 2002 B1
6433033 Isobe et al. Aug 2002 B1
6437006 Yoon et al. Aug 2002 B1
6440429 Torizuka et al. Aug 2002 B1
6447801 Salafsky et al. Sep 2002 B1
6455076 Hahn et al. Sep 2002 B1
6468989 Chang et al. Oct 2002 B1
6479058 McCadden Nov 2002 B1
6486168 Skwierczynski et al. Nov 2002 B1
6488947 Bekele Dec 2002 B1
6511655 Muller et al. Jan 2003 B1
6514487 Barr Feb 2003 B1
6524594 Santora et al. Feb 2003 B1
6531118 Gonzalez et al. Mar 2003 B1
6534455 Maurin et al. Mar 2003 B1
6536629 van der Heijden Mar 2003 B2
6544530 Friedman Apr 2003 B1
6544562 Singh et al. Apr 2003 B2
6547063 Zaveri et al. Apr 2003 B1
6548074 Mohammadi Apr 2003 B1
6562355 Renault May 2003 B1
6566350 Ono et al. May 2003 B2
6582679 Stein et al. Jun 2003 B2
6582710 Deckers et al. Jun 2003 B2
6589509 Keller et al. Jul 2003 B2
6596287 Deckers et al. Jul 2003 B2
6599513 Deckers et al. Jul 2003 B2
6620773 Stork et al. Sep 2003 B1
6638981 Williams et al. Oct 2003 B2
6649571 Morgan Nov 2003 B1
6649574 Cardis et al. Nov 2003 B2
6672483 Roy Jan 2004 B1
6682726 Marchesi et al. Jan 2004 B2
6691898 Hurray et al. Feb 2004 B2
6709663 Espinoza Mar 2004 B2
6723309 Deane Apr 2004 B1
6730288 Abram May 2004 B1
6753000 Breton et al. Jun 2004 B2
6753167 Moloney et al. Jun 2004 B2
6762158 Lukenbach et al. Jul 2004 B2
6765001 Gans et al. Jul 2004 B2
6774114 Castiel et al. Aug 2004 B2
6777591 Chaudhary et al. Aug 2004 B1
6790435 Ma et al. Sep 2004 B1
6796973 Contente et al. Sep 2004 B1
RE38623 Hernandez et al. Oct 2004 E
6811767 Bosch et al. Nov 2004 B1
6834778 Jinbo et al. Dec 2004 B2
6843390 Bristor Jan 2005 B1
6875438 Kraemer et al. Apr 2005 B2
6881271 Ochiai et al. Apr 2005 B2
6890567 Nakatsu et al. May 2005 B2
6902737 Quemin et al. Jun 2005 B2
6911211 Eini et al. Jun 2005 B2
6946120 Wai-Chiu So et al. Sep 2005 B2
6946139 Henning Sep 2005 B2
6951654 Malcolm et al. Oct 2005 B2
6955816 Klysz Oct 2005 B2
6956062 Beilfuss et al. Oct 2005 B2
6958154 Andolino Brandt et al. Oct 2005 B2
6967012 Eini et al. Nov 2005 B2
6967023 Eini et al. Nov 2005 B1
6968982 Burns Nov 2005 B1
6969521 Gonzalez et al. Nov 2005 B1
RE38964 Shillington Jan 2006 E
6994863 Eini et al. Feb 2006 B2
7002486 Lawrence Feb 2006 B2
7014844 Mahalingam et al. Mar 2006 B2
7021499 Hansen et al. Apr 2006 B2
7029659 Abram Apr 2006 B2
7060253 Mundschenk Jun 2006 B1
7078058 Jones et al. Jul 2006 B2
7083799 Giacomoni Aug 2006 B1
7137536 Walters et al. Nov 2006 B2
7195135 Garcia Mar 2007 B1
7222802 Sweeton May 2007 B2
7225518 Eidenschink et al. Jun 2007 B2
7226230 Liberatore Jun 2007 B2
7235251 Hamer et al. Jun 2007 B2
7270828 Masuda et al. Sep 2007 B2
7455195 Mekata Nov 2008 B2
7497354 Decottignies et al. Mar 2009 B2
7575739 Tamarkin et al. Aug 2009 B2
7645803 Tamarkin et al. Jan 2010 B2
7654415 van der Heijden Feb 2010 B2
7682523 Eini et al. Mar 2010 B2
7682623 Eini et al. Mar 2010 B2
7700076 Tamarkin et al. Apr 2010 B2
7704518 Tamarkin et al. Apr 2010 B2
7793807 Goujon et al. Sep 2010 B2
7820145 Tamarkin et al. Oct 2010 B2
7960416 Sato et al. Jun 2011 B2
20010006654 Cannell et al. Jul 2001 A1
20010027218 Stern et al. Oct 2001 A1
20010027981 Vlodek Oct 2001 A1
20010036450 Verite et al. Nov 2001 A1
20020002151 Ono et al. Jan 2002 A1
20020004063 Zhang Jan 2002 A1
20020013481 Schonrock et al. Jan 2002 A1
20020015721 Simonnet et al. Feb 2002 A1
20020032171 Chen et al. Mar 2002 A1
20020035046 Lukenbach et al. Mar 2002 A1
20020035070 Gardlik et al. Mar 2002 A1
20020035087 Barclay Mar 2002 A1
20020035182 L'Alloret et al. Mar 2002 A1
20020039591 Dahle Apr 2002 A1
20020044659 Ohta Apr 2002 A1
20020045659 Michelet et al. Apr 2002 A1
20020048798 Avery et al. Apr 2002 A1
20020058010 Picard-Lesboueyries et al. May 2002 A1
20020072544 Miller et al. Jun 2002 A1
20020090386 Haslwanter et al. Jul 2002 A1
20020098215 Douin et al. Jul 2002 A1
20020111281 Vishnupad Aug 2002 A1
20020117516 Lasserre et al. Aug 2002 A1
20020134376 Castro et al. Sep 2002 A1
20020136755 Tyrrell et al. Sep 2002 A1
20020143188 Garvey et al. Oct 2002 A1
20020153390 Vlodek Oct 2002 A1
20020165170 Wilson et al. Nov 2002 A1
20020182162 Shahinpoor et al. Dec 2002 A1
20020187181 Godbey et al. Dec 2002 A1
20020198136 Mak et al. Dec 2002 A1
20030006193 Ikeda et al. Jan 2003 A1
20030031693 Breton et al. Feb 2003 A1
20030053961 Eccard Mar 2003 A1
20030077297 Chen et al. Apr 2003 A1
20030078172 Guiramand et al. Apr 2003 A1
20030114520 Pereira et al. Jun 2003 A1
20030118515 Jew et al. Jun 2003 A1
20030130247 Gans et al. Jul 2003 A1
20030175232 Elliott et al. Sep 2003 A1
20030175315 Yoo et al. Sep 2003 A1
20030180347 Young et al. Sep 2003 A1
20030185839 Podolsky Oct 2003 A1
20030194379 Brugger et al. Oct 2003 A1
20030195128 Deckman et al. Oct 2003 A1
20030206955 Sonneville-Aubrun et al. Nov 2003 A1
20030215472 Bonda et al. Nov 2003 A1
20040018228 Fischell et al. Jan 2004 A1
20040028752 Kamm et al. Feb 2004 A1
20040038912 Michelet et al. Feb 2004 A1
20040053797 Chen et al. Mar 2004 A1
20040058878 Walker Mar 2004 A1
20040063787 Villanueva Apr 2004 A1
20040067970 Foster et al. Apr 2004 A1
20040072638 Enos et al. Apr 2004 A1
20040076651 Brocks et al. Apr 2004 A1
20040078896 Hellyer et al. Apr 2004 A1
20040079361 Clayton et al. Apr 2004 A1
20040105825 Henning Jun 2004 A1
20040120917 Perrier et al. Jun 2004 A1
20040127554 Ghisalberti Jul 2004 A1
20040138179 Goldstein et al. Jul 2004 A1
20040151671 Abram et al. Aug 2004 A1
20040151756 Richards et al. Aug 2004 A1
20040161447 Paul Aug 2004 A1
20040184992 Abram Sep 2004 A1
20040185123 Mazzio et al. Sep 2004 A1
20040191196 Tamarkin Sep 2004 A1
20040192754 Shapira et al. Sep 2004 A1
20040195276 Fuchs Oct 2004 A1
20040197276 Takase et al. Oct 2004 A1
20040197295 Riedel et al. Oct 2004 A1
20040219122 Masuda et al. Nov 2004 A1
20040219176 Dominguez Nov 2004 A1
20040220187 Stephenson et al. Nov 2004 A1
20040229813 DiPiano et al. Nov 2004 A1
20040234475 Lannibois-Drean et al. Nov 2004 A1
20040241099 Popp et al. Dec 2004 A1
20040247531 Riedel et al. Dec 2004 A1
20040253275 Eini et al. Dec 2004 A1
20040258627 Riedel et al. Dec 2004 A1
20040265240 Tamarkin et al. Dec 2004 A1
20050002976 Wu Jan 2005 A1
20050013853 Gil-Ad et al. Jan 2005 A1
20050031547 Tamarkin et al. Feb 2005 A1
20050042182 Arkin et al. Feb 2005 A1
20050054991 Tobyn et al. Mar 2005 A1
20050069566 Tamarkin et al. Mar 2005 A1
20050074414 Tamarkin et al. Apr 2005 A1
20050075407 Tamarkin et al. Apr 2005 A1
20050079139 Jacques et al. Apr 2005 A1
20050084551 Jensen et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050101936 Gonzales et al. May 2005 A1
20050106197 Blin et al. May 2005 A1
20050123494 Swaile et al. Jun 2005 A1
20050123496 Shah et al. Jun 2005 A1
20050186142 Tamarkin et al. Aug 2005 A1
20050186147 Tamarkin et al. Aug 2005 A1
20050189377 Lanzendorfer et al. Sep 2005 A1
20050196414 Dake et al. Sep 2005 A1
20050205086 Tamarkin et al. Sep 2005 A1
20050207837 Kosh et al. Sep 2005 A1
20050222090 Cheng et al. Oct 2005 A1
20050232869 Tamarkin et al. Oct 2005 A1
20050244342 Friedman et al. Nov 2005 A1
20050244354 Speron Nov 2005 A1
20050245902 Cornish et al. Nov 2005 A1
20050252995 Westphal et al. Nov 2005 A1
20050255048 Hirsh et al. Nov 2005 A1
20050258189 Peterson et al. Nov 2005 A1
20050266035 Healy et al. Dec 2005 A1
20050268416 Sommers Dec 2005 A1
20050271596 Friedman et al. Dec 2005 A1
20050271598 Friedman et al. Dec 2005 A1
20050276836 Wilson et al. Dec 2005 A1
20050281755 Zarif et al. Dec 2005 A1
20050281766 Martin et al. Dec 2005 A1
20050285912 Delametter et al. Dec 2005 A1
20050287081 Aust et al. Dec 2005 A1
20060008432 Scarampi et al. Jan 2006 A1
20060018937 Friedman et al. Jan 2006 A1
20060018938 Neubourg Jan 2006 A1
20060029565 Xu et al. Feb 2006 A1
20060051301 Galopin et al. Mar 2006 A1
20060054634 Mekata Mar 2006 A1
20060057168 Larm et al. Mar 2006 A1
20060088561 Eini et al. Apr 2006 A1
20060099151 Neubourg May 2006 A1
20060108377 Glynn et al. May 2006 A1
20060110418 Johnson May 2006 A1
20060014990 Bortz et al. Jun 2006 A1
20060114745 Ollmann et al. Jun 2006 A1
20060121073 Goyal et al. Jun 2006 A1
20060140984 Tamarkin et al. Jun 2006 A1
20060140990 Bortz et al. Jun 2006 A1
20060160713 Sekine et al. Jul 2006 A1
20060165616 Brock et al. Jul 2006 A1
20060177392 Walden Aug 2006 A1
20060193789 Tamarkin et al. Aug 2006 A1
20060193813 Simonnet Aug 2006 A1
20060204446 Lulla et al. Sep 2006 A1
20060222675 Sabnis et al. Oct 2006 A1
20060233721 Tamarkin et al. Oct 2006 A1
20060239937 Neubourg Oct 2006 A2
20060251684 Annis et al. Nov 2006 A1
20060254597 Thompson Nov 2006 A1
20060263323 Hoang et al. Nov 2006 A1
20060269485 Friedman et al. Nov 2006 A1
20060272199 Licciardello et al. Dec 2006 A1
20060275218 Tamarkin et al. Dec 2006 A1
20060275221 Tamarkin et al. Dec 2006 A1
20060285912 Eini et al. Dec 2006 A1
20060292080 Abram et al. Dec 2006 A1
20070009607 Jones Jan 2007 A1
20070017696 Lin et al. Jan 2007 A1
20070020213 Tamarkin et al. Jan 2007 A1
20070020304 Tamarkin et al. Jan 2007 A1
20070027055 Koivisto et al. Feb 2007 A1
20070036831 Baker Feb 2007 A1
20070059253 Popp et al. Mar 2007 A1
20070069046 Eini et al. Mar 2007 A1
20070071688 Illel et al. Mar 2007 A1
20070098647 Neubourg May 2007 A1
20070134174 Irwin et al. Jun 2007 A1
20070140999 Puglia et al. Jun 2007 A1
20070142263 Stahl et al. Jun 2007 A1
20070148112 Dingley et al. Jun 2007 A1
20070148194 Amiji et al. Jun 2007 A1
20070154402 Trumbore et al. Jul 2007 A1
20070160548 Riccardi et al. Jul 2007 A1
20070237724 Abram et al. Oct 2007 A1
20070253911 Tamarkin et al. Nov 2007 A1
20070264317 Yosha et al. Nov 2007 A1
20070271235 Frank et al. Nov 2007 A1
20070280891 Tamarkin et al. Dec 2007 A1
20070281999 Fox et al. Dec 2007 A1
20070292355 Tamarkin et al. Dec 2007 A1
20070292359 Friedman et al. Dec 2007 A1
20070292461 Tamarkin et al. Dec 2007 A1
20080008397 Kisilev Jan 2008 A1
20080015263 Bolotin et al. Jan 2008 A1
20080015271 Abram et al. Jan 2008 A1
20080031907 Tamarkin et al. Feb 2008 A1
20080031908 Aubrun-Sonneville et al. Feb 2008 A1
20080035155 Dahl Feb 2008 A1
20080044444 Tamarkin et al. Feb 2008 A1
20080058055 LeMay et al. Mar 2008 A1
20080063682 Cashman et al. Mar 2008 A1
20080069779 Tamarkin et al. Mar 2008 A1
20080131378 Keller et al. Jun 2008 A1
20080138293 Tamarkin et al. Jun 2008 A1
20080138296 Tamarkin et al. Jun 2008 A1
20080152596 Friedman et al. Jun 2008 A1
20080153789 Dmowski et al. Jun 2008 A1
20080166303 Tamarkin et al. Jul 2008 A1
20080167376 Bar-Or et al. Jul 2008 A1
20080181854 Eini et al. Jul 2008 A1
20080188445 Muldoon et al. Aug 2008 A1
20080188446 Muldoon et al. Aug 2008 A1
20080193762 Dubertret et al. Aug 2008 A1
20080206155 Tamarkin et al. Aug 2008 A1
20080206159 Tamarkin et al. Aug 2008 A1
20080206161 Tamarkin et al. Aug 2008 A1
20080241079 Neubourg Oct 2008 A1
20080253973 Tamarkin et al. Oct 2008 A1
20080255498 Houle Oct 2008 A1
20080260655 Tamarkin et al. Oct 2008 A1
20080292560 Tamarkin et al. Nov 2008 A1
20080299220 Tamarkin et al. Dec 2008 A1
20080311167 Oronsky et al. Dec 2008 A1
20080317679 Tamarkin et al. Dec 2008 A1
20090041680 Tamarkin et al. Feb 2009 A1
20090068118 Eini et al. Mar 2009 A1
20090090558 Tamarkin et al. Apr 2009 A1
20090093514 Statham et al. Apr 2009 A1
20090130029 Tamarkin et al. May 2009 A1
20090131488 Harel et al. May 2009 A1
20090175799 Tamarkin et al. Jul 2009 A1
20090180970 Tamarkin et al. Jul 2009 A1
20090291917 Akama et al. Nov 2009 A1
20090317338 Tamarkin et al. Dec 2009 A1
20100111879 Tamarkin et al. May 2010 A1
20100221194 Loupenok Sep 2010 A1
20110002857 Tamarkin et al. Jan 2011 A1
20110002969 Serraima et al. Jan 2011 A1
20110212033 Tamarkin et al. Sep 2011 A1
20110268665 Tamarkin et al. Nov 2011 A1
Foreign Referenced Citations (312)
Number Date Country
198780257 Sep 1986 AU
2422244 Sep 2003 CA
639913 Dec 1983 CH
1 882 100 Nov 1963 DE
1926796 Nov 1965 DE
4140474 Jun 1993 DE
10009233 Aug 2000 DE
10138495 Feb 2003 DE
102004016710 Oct 2005 DE
2 608 226 Sep 2007 DE
0 156 507 Oct 1985 EP
0 186 453 Jul 1986 EP
0 211 550 Feb 1987 EP
0 214 865 Mar 1987 EP
0 216 856 Apr 1987 EP
0 270 316 Jun 1988 EP
0 297 436 Jan 1989 EP
0 326 196 Aug 1989 EP
0 336 812 Oct 1989 EP
0 391 124 Oct 1990 EP
0 404 376 Dec 1990 EP
0 414 920 Mar 1991 EP
0 484 530 May 1992 EP
0 485 299 May 1992 EP
0 488 089 Jun 1992 EP
0 504 301 Sep 1992 EP
0 528 190 Feb 1993 EP
0 535 327 Apr 1993 EP
0 552 612 Jul 1993 EP
0 569 773 Nov 1993 EP
0 598 412 May 1994 EP
0 662 431 Jul 1995 EP
0 676 198 Oct 1995 EP
0 738 516 Oct 1996 EP
0 757 959 Feb 1997 EP
0 824 911 Feb 1998 EP
0 829 259 Mar 1998 EP
0 928 608 Jul 1999 EP
0 979 654 Feb 2000 EP
0 993 827 Apr 2000 EP
1 025 836 Aug 2000 EP
1 055 425 Nov 2000 EP
0 506 197 Jul 2001 EP
1 215 258 Jun 2002 EP
1 287 813 Mar 2003 EP
1 308 169 May 2003 EP
1 375 386 Jan 2004 EP
1 428 521 Jun 2004 EP
1 438 946 Jul 2004 EP
1 189 579 Sep 2004 EP
1 475 381 Nov 2004 EP
1 483 001 Dec 2004 EP
1 500 385 Jan 2005 EP
1 537 916 Jun 2005 EP
1 600 185 Nov 2005 EP
1 734 927 Dec 2006 EP
1 758 547 Mar 2007 EP
1 584 324 Nov 2007 EP
1 889 609 Feb 2008 EP
2 591 331 Jun 1987 FR
2 640 942 Jun 1990 FR
2 736 824 Jan 1997 FR
2 774 595 Aug 1999 FR
2 789 371 Aug 2000 FR
2 793 479 Nov 2000 FR
2 814 959 Apr 2002 FR
2 833 246 Jun 2003 FR
2 840 903 Dec 2003 FR
2 843 373 Feb 2004 FR
2 845 672 Apr 2004 FR
2 848 998 Jun 2004 FR
2 860 976 Apr 2005 FR
2 915 891 Nov 2008 FR
808 104 Jan 1959 GB
808 105 Jan 1959 GB
922 930 Apr 1963 GB
933 486 Aug 1963 GB
998 490 Jul 1965 GB
1 026 831 Apr 1966 GB
1 033 299 Jun 1966 GB
1 081 949 Sep 1967 GB
1 121 358 Jul 1968 GB
1 162 684 Aug 1969 GB
1 170 152 Nov 1969 GB
1 201 918 Aug 1970 GB
1 347 950 Feb 1974 GB
1 351 761 May 1974 GB
1 351 762 May 1974 GB
1 353 381 May 1974 GB
1 376 649 Dec 1974 GB
1 397 285 Jun 1975 GB
1 408 036 Oct 1975 GB
1 457 671 Dec 1976 GB
1 489 672 Oct 1977 GB
2 004 746 Apr 1979 GB
1 561 423 Feb 1980 GB
2 114 580 Aug 1983 GB
2 153 686 Aug 1985 GB
2 172 298 Sep 1986 GB
2 206 099 Dec 1988 GB
2 166 651 May 1996 GB
2 337 461 Nov 1999 GB
2 367 809 Apr 2002 GB
2 406 330 Mar 2005 GB
2 406 791 Apr 2005 GB
49491 Sep 1979 IL
152 486 May 2003 IL
60001113 Apr 1978 JP
55069682 May 1980 JP
57044429 Mar 1982 JP
56039815 Apr 1984 JP
61275395 Dec 1986 JP
62241701 Oct 1987 JP
63119420 May 1988 JP
1100111 Apr 1989 JP
1156906 Jun 1989 JP
2184614 Jul 1990 JP
2255890 Oct 1990 JP
4282311 Oct 1992 JP
4312521 Nov 1992 JP
5070340 Mar 1993 JP
5213734 Aug 1993 JP
6100414 Apr 1994 JP
H06-263630 Jun 1994 JP
6329532 Nov 1994 JP
2007155667 Jun 1995 JP
7215835 Aug 1995 JP
2008040899 Feb 1996 JP
8501529 Feb 1996 JP
8119831 May 1996 JP
8165218 Jun 1996 JP
8277209 Oct 1996 JP
09 084855 Mar 1997 JP
9099553 Apr 1997 JP
9110636 Apr 1997 JP
10114619 May 1998 JP
3050289 Sep 1998 JP
2010332456 Dec 1998 JP
11501045 Jan 1999 JP
11250543 Sep 1999 JP
2000017174 Jan 2000 JP
2000080017 Mar 2000 JP
2000128734 May 2000 JP
2000191429 Jul 2000 JP
2000239140 Sep 2000 JP
2000351726 Dec 2000 JP
2000354623 Dec 2000 JP
2001002526 Jan 2001 JP
2001019606 Jan 2001 JP
2001072963 Mar 2001 JP
2002012513 Jan 2002 JP
2002047136 Feb 2002 JP
2002524490 Aug 2002 JP
2002302419 Oct 2002 JP
2003012511 Jan 2003 JP
2003055146 Feb 2003 JP
2004047136 Feb 2004 JP
2004250435 Sep 2004 JP
2004348277 Dec 2004 JP
2005314323 Nov 2005 JP
2005350378 Dec 2005 JP
2006008574 Jan 2006 JP
2006036317 Feb 2006 JP
2006103799 Apr 2006 JP
2006525145 Nov 2006 JP
2007131539 May 2007 JP
S48-92282 Mar 2012 JP
143232 Jul 1998 KR
2001003063 Jan 2001 KR
2277501 Jun 2006 RU
66796 Jun 2004 UA
8201821 Jun 1982 WO
8605389 Sep 1986 WO
8801502 Mar 1988 WO
8801863 Mar 1988 WO
8808316 Nov 1988 WO
8906537 Jul 1989 WO
9005774 May 1990 WO
9111991 Aug 1991 WO
9200077 Jan 1992 WO
9205142 Apr 1992 WO
9205763 Apr 1992 WO
9211839 Jul 1992 WO
9325189 Dec 1993 WO
9406440 Mar 1994 WO
9603115 Feb 1996 WO
9619921 Jul 1996 WO
9624325 Aug 1996 WO
9626711 Sep 1996 WO
9627376 Sep 1996 WO
9639119 Dec 1996 WO
9703638 Feb 1997 WO
9739745 Oct 1997 WO
9817282 Apr 1998 WO
9818472 May 1998 WO
9819654 May 1998 WO
9821955 May 1998 WO
9823291 Jun 1998 WO
9836733 Aug 1998 WO
9852536 Nov 1998 WO
9908649 Feb 1999 WO
9920250 Apr 1999 WO
9937282 Jul 1999 WO
9953923 Oct 1999 WO
0009082 Feb 2000 WO
0015193 Mar 2000 WO
0023051 Apr 2000 WO
0033825 Jun 2000 WO
0038731 Jul 2000 WO
0061076 Oct 2000 WO
0076461 Dec 2000 WO
0105366 Jan 2001 WO
0108681 Feb 2001 WO
0110961 Feb 2001 WO
0153198 Jul 2001 WO
0154212 Jul 2001 WO
0154679 Aug 2001 WO
0162209 Aug 2001 WO
0170242 Sep 2001 WO
0182880 Nov 2001 WO
0182890 Nov 2001 WO
0185102 Nov 2001 WO
0185128 Nov 2001 WO
0195728 Dec 2001 WO
0200820 Jan 2002 WO
0215860 Feb 2002 WO
0215873 Feb 2002 WO
0228435 Apr 2002 WO
0241847 May 2002 WO
0243490 Jun 2002 WO
0262324 Aug 2002 WO
0278667 Oct 2002 WO
0287519 Nov 2002 WO
03000223 Jan 2003 WO
03002082 Jan 2003 WO
03013984 Feb 2003 WO
03051294 Jun 2003 WO
03053292 Jul 2003 WO
03055445 Jul 2003 WO
03055454 Jul 2003 WO
03070301 Aug 2003 WO
03071995 Sep 2003 WO
03075851 Sep 2003 WO
03092641 Nov 2003 WO
03097002 Nov 2003 WO
2004017962 Mar 2004 WO
2004037197 May 2004 WO
2004037225 May 2004 WO
2004003284 Aug 2004 WO
2004064769 Aug 2004 WO
2004064833 Aug 2004 WO
2004071479 Aug 2004 WO
2004078158 Sep 2004 WO
2004078896 Sep 2004 WO
2004093895 Nov 2004 WO
2004112780 Dec 2004 WO
2005011567 Feb 2005 WO
2005018530 Mar 2005 WO
2005032522 Apr 2005 WO
2005044219 May 2005 WO
2005063224 Jul 2005 WO
2005065652 Jul 2005 WO
2005076697 Aug 2005 WO
2005097068 Oct 2005 WO
2005102282 Nov 2005 WO
2005102539 Nov 2005 WO
2005117813 Dec 2005 WO
2006003481 Jan 2006 WO
2006010589 Feb 2006 WO
2006011046 Feb 2006 WO
2006020682 Feb 2006 WO
2006028339 Mar 2006 WO
2006031271 Mar 2006 WO
2006045170 May 2006 WO
2006079632 Aug 2006 WO
2006081327 Aug 2006 WO
2006091229 Aug 2006 WO
2006100485 Sep 2006 WO
2006120682 Nov 2006 WO
2006121610 Nov 2006 WO
2006122158 Nov 2006 WO
2006129161 Dec 2006 WO
2006131784 Dec 2006 WO
2007007208 Jan 2007 WO
2007012977 Feb 2007 WO
2007023396 Mar 2007 WO
2007031621 Mar 2007 WO
2007039825 Apr 2007 WO
2007050543 May 2007 WO
2007054818 May 2007 WO
2007072216 Jun 2007 WO
2007085899 Aug 2007 WO
2007085902 Aug 2007 WO
2007099396 Sep 2007 WO
2007111962 Oct 2007 WO
2008008397 Jan 2008 WO
2008010963 Jan 2008 WO
2008038147 Apr 2008 WO
2008041045 Apr 2008 WO
2008075207 Jun 2008 WO
2008087148 Jul 2008 WO
2008110872 Sep 2008 WO
2008152444 Dec 2008 WO
2009007785 Jan 2009 WO
2009069006 Jun 2009 WO
2009072007 Jun 2009 WO
2009087578 Jul 2009 WO
2009090495 Jul 2009 WO
2009090558 Jul 2009 WO
2009098595 Aug 2009 WO
2011039637 Apr 2011 WO
2011039638 Apr 2011 WO
Non-Patent Literature Citations (257)
Entry
U.S. Appl. No. 60/789,186, Tamarkin, Apr. 4, 2006.
U.S. Appl. No. 60/815,948, Tamarkin, Jun. 23, 2006.
U.S. Appl. No. 60/818,634, Friedman, Jul. 5, 2006.
U.S. Appl. No. 60/843,140, Tamarkin, Sep. 8, 2006.
U.S. Appl. No. 61/248,144, Tamarkin, Oct. 2, 2009.
U.S. Appl. No. 61/322,148, Tamarkin, Apr. 8, 2010.
U.S. Appl. No. 61/363,577, Eini, Jul. 12, 2010.
“Burn patients need vitamin D supplements.” Decision News Media, Jan. 23, 2004, http://www.nutraingredients.com/Research/Burn-patients-need-vitamin-D-supplements, Accessed: May 5, 2010.
“HLB Systems”, http://pharmcal.tripod.com/ch17.htm, Accessed Sep. 17, 2010, pp. 1-3.
“Minocycline” accessed on Oct. 21, 2011 at en.wikipedia.org/wiki/Minocycline, 7 pages.
“Reaction Rate” Accessed at en.wikipedia.org/wiki/Reaction—rate on Dec. 18, 2011, 6 pages.
‘Niram Chemicals’ [online]. Niram Chemicals, [retrieved on Jul. 17, 2012]. Retrieved from the Internet: <URL: http://www.indiamart.com/niramchemicals/chemicals.html>, 7 pages.
‘Surfactant’ [online]. Wikipedia, 2010, [retrieved on Oct. 24, 2010]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Surfactant>, 7 pages.
Adachi, Shuji. “Storage and Oxidative Stability of O/W/ Nano-emulsions.” Foods Food Ingredients. J. Jpn. vol. 209, No. 11. 2004. 1 page.
Alcohol SDA 40B.http://www.pharmco-prod.com/pp./MSDS/SDA.sub.—40B.sub.—200.pdf Accessed Dec. 9, 2008, 2 pages.
Ambrose, Ursula et al., “In Vitro Studies of Water Activity and Bacterial Growth Inhibition of Sucrose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400- Hydrogen Peroxide Pastes Used to Treat Infected Wounds,”Antimicrobial Agents and Chemotherapy, vol. 35, No. 9, pp. 1799-1803, 1991.
Anton, N. et al. “Water-in-Oil Nano-Emulsion Formation by the phase Method: A Novel and General Concept, a New Template for Nanoencapsulation,” Proceedings of the 33rd Annual Meeting and Exposition of the Controlled Release Society, Jul. 2006, Vienna Austria, 2 pages.
Arct et al., “Common Cosmetic Hydrophilic Ingredients as Penetration Modifiers of Flavonoids”, International Journal of Cosmetic Science, 24(6):357-366 (2002)—Abstract, 1 page.
Arisan, http://www.arisankimya.corn/kozmetik.htm Accessed Dec. 10, 2008, 8 pages.
Augsburger, Larry L. et al. “Bubble Size Analysis of High Consistency Aerosol Foams and Its Relationship to Foam Rheology. Effects of Container Emptying, Propellent Type, and Time.” Journal of Pharmaceutical Sciences. vol. 57, No. 4. Apr. 1968. pp. 624-631.
Austria, et al., “Stability of Vitamin C Derivatives in Solution and Topical Formulations”, Journal of Pharmaceutical and Biomedical Analysis, 15:795-801 (1997).
Barry and Badal, “Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays,” Current Microbiology, 1978, 1:33-36.
Barry, B.W. et al, Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments, British Journal of Dermatology, 93, 563-571, 1975.
Benet, et al., Application of NMR for the Determination of HLB Values of Nonionic Surfactants, Journal of the American Oil Chemists Society, vol. 49, 1972, 499-500.
Bernstein, et al., Effects of the Immunomodulating Agent R837 on Acute and Latent Herpes Simplex Virus Type 2 Invections, Antimicrobial Agents and Chemotherapy, 33(9):1511-1515 (1989).
Blute, “Phase behavior of alkyl glycerol ether surfacants”, Physical Chemistry Tenside Sur. Det., 35(3):207-212 (1998).
Brenes, et al., “Stability of Copigmented Anthocyanins and Asorbics Acid in a Grape Juice Model System”, J. Agric Food Chem, 53(1):49-56 (2005)—Abstrace, 1 page.
Bronopol. Revtrieved online on Jun. 4, 2011. <URL:http://chemicalland21.com/specialtychern/perchem/BRONOPOL.html>. Jul. 17, 2006. 4 pages.
Buck, et al., “Treatment of Vaginal Intraephithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream”, Journal of Lower Genetial Tract Disease, 7(3):290-293 (2003).
Bucks, Daniel a.W., et al., “Bioavailability of Topically Administered Steroids: A ‘Mass Balance’ Technique,” Journal of Investigative Dermatology, vol. 91, No. 1, Jul. 1988, pp. 29-33.
Bunker,et al., “Alterations in Scalp Blood Flow after the Epicutaneous Application of 3% Minoxidil and 0.1% Hexyl Nicotinate in Alopecia”, Presented as a poster at the meeting of the British Society for Investigavie Dermatology, York, Sep. 1986 (2 pages).
Burton, et al., “Hypertrichosis Due to Minoxidil”, British Journal of Dermatology, 101:593-595 (1979).
Campos, et al., “Ascorbic Acid and Its Derivatives in Cosmetic Formulations”, Cosmetics and Toiletries, 115(6):59-62 (2000) - Abstract, 1 page.
Carbowax 1000MSDS; http://www.sciencelab.com/xMSDS-Polyethylene.sub.—glycol.sub.—1000-9926-622. Accessed Dec. 13, 2008, 6 pages.
Carelli, et al., “Effect of Vehicles on Yohimbine Permeation Across Excised Hairless Mouse Skin”, Pharm Acta Helv, 73(3):127-134 (1998)—Abstract, 1 page.
Chebil, et al., “Soulbility of Flavonoids in Organic Solvents”, J. Chem. Eng. Data, 52(5):1552- 1556 (2007) - Abstract, 1 page.
Cheshire, et al., Disorders of Sweating, www.medscape.com, Semin Neurol 23(4):399-406, 2003.
Chevrant-Breton, et al., “Etude du Traitement Capillaire <<Bioscalin>> dans les Alopecies Diffuses de la Femme”, Gazette Medicale, 93(17):75-79 (1986) [English abstract].
Chiang, et al., “Bioavailability Assessment of Topical Delivery Systems: In Vitro Delivery of Minoxidil from Prototypical Semi-Solid Formulations”, Int. J. Pharm, 49(2):109-114 (1989)—Abstract, 1 page.
Chinnian, et al., “Photostability Profiles of Minoxidil Solutions”, PDA J. Pharm Sci Technol., 50(2):94-98 (1996)—Abstract, 1 page.
Chollet, et al., “Development of a Topically Active Imiquimod Formulation”, Pharmaceutical Development and Technology, 4(1):35-43 (1999).
Chollet, et al., “The Effect of Temperatures on the Solubility of Immiquimod in Isostearic Acid”, Abstract 3031, Pharmaceutical Research, vol. 14, No. 11 Supplemental (Nov.), p. S475 (1997), 2 pages.
Coetzee, “Acceptability and Feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides,” NicolAIDS 2001, vol. 15, No. 14, pp. 1837-1842.
Colloidal Silica. Retrieved online on Jun. 4, 2011. <URL:http://www.grace.com/engineeredmaterials/materialsciences/colloidalsilica/default.aspx>. Copyright 2011. 4 pages.
Croda 2. Croda Cetomacrogol 1000 Product Information Sheet. 2011 (no month given). 1 page.
Croda. Aracel 165 Product Summary. 2011 (no month given). 1 page.
D.W.A. Sharp Dictionary of Chemistry, Penguin Books, 1983, 3 pages.
Dalby, “Determination of Drug Solubility in Aerosol Propellants,” Pharmaceutical Research, vol. 8, No. 9, 1991, pp. 1206-1209.
Dawber, et al., “Hypertrichosis in Females Applying Minoxidil Topical Solution and in Normal Controls”, JEADV, 17:271-275 (2003).
Denatonium Benzoate http://www.newdruginfo.com/pharmaceopeia/usp28/v28230/usp28nf23s0.sub.--m- 22790.htm Accessed Dec. 9, 2008, 2 pages.
Dentinger, et al., “Stability of Nifedipine in an Extemporaneously Compounded Oral Solution”, American Journal of Health-System Pharmacy, 60(10):1019-1022 (2003)—Abstract, 1 page.
disorder. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/disorder. 1 page.
Draelos, Z. D. “Antiperspirants and the Hyperhidrosis Patients.” Dermatologic Therapy. 2001. vol. 14. pages 220-224.
Edens, et al., “Storage Stability and Safey of Active Vitamin C in a New Dual-Chamber Dispenser”, Journal of Applied Cosmetology, 17(4):136-143 (1999)—Abstract, 1 page.
Edirisinghe, et al., “Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta”, Clin Sci (Lond). Aug. 2006; 111(2): 145-51.
Edwards, “Imiquimod in Clinical Practice”, J. Am Acad Dermatol., 43(1, Pt 2):512-517 (2000)—Abstract, 1 page.
Emulsifiers with HLB values. http://www.theherbarie.com/files/resources-center/formulating/Emulsifiers-.sub.—HLB.sub.--Values.pdf accessed Aug. 5, 2009 (3 pps).
Encyclopedia of Pharmaceutical Technology, Second Edition, vol. 3, Copyright 2002, 4 pages.
Esposito, E. et al. “Nanosystems for Skin Hydration: A Comparative Study.” International Journal of Cosmetic Science. 29. 2007. pages. 39-47.
Ethanol, Accessed http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=E7023SIAL&N5=SEAR- CH.sub.—Concat.sub.—PNOBRAND.sub.--KEY&F=SPEC Dec. 9, 2008, 2 pages.
Ethylene Oxide Derivatives: An Essence of Every Industry. A definition of Emulsifier. Http://www.emulsifiers.In/ethylene—oxide—derivatives2.htm. Accessed Jul. 12, 2011. 3 pages.
Farahmand, et al., “Formulation and Evaluation of a Vitamin C Multiple Emulsion”, Pharmaceutical Development and Technology, 11(2):255-261 (2006)—Abstract, 1 page.
Final Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., Dec. 16, 2008, 24 pages.
Flick, Cosmetic and Toiletry Formulations, vol. 5, 2nd Edition, Copyright 1996, 63 pages. Relevant pp. 251-309.
Fontana, Anthony J., “Water Activity: Why It is Important for Food Safety,” International Conference on Food Safety, Nov. 16-18, 1998, pp. 177-185.
Gallarate, et al., “On the Stability of Ascorbic Acid in Emulsified Systems for Topical and Cosmetic Use”, International Journal of Pharmaceutics, 188:233-241 (1999).
Galligan, John et al., “Adhesive Polyurethane Liners for Anterior Restorations,” J. Dent. Res., Jul.-Aug. 1968, pp. 629-632.
Gelbard et al. “Primary Pediatric Hyperhidrosis: A Review of Current Treatment Options.” Pediatric Dermatology. 2008. 25 (6). pp. 591-598.
Gill, A.M, et al., “Adverse Drug Reactions in a Paediatric Intensive Care Unit,” Acta Paediatr 84:438-441, 1995.
Gladkikh, “Ascorbic Acid and Methods of Increasing its Stability in Drugs”, Translated from Khimiko-Farmatsevticheskii Zhurnal, 4(12):37-42 (1970)—1 page.
Glaser, et al., Hyperhidrosis: A Comprehensive and Practical Approach to Patient Management, Expert Rev. Dermatol. 1(6), 773-775 (2006).
Graves, S. et al. “Structure of Concentrated Nanoemulsions.” The Journal of Chemical Physics.. 122 America Institute of Physics. Published Apr. 1, 2005. 6 pages.
Groveman, et al., “Lack of Efficacy of Polysorbate 60 in the Treatment of Male Pattern Baldness”, Arch Intern Med, 145:1454-1458 (1985).
Gschnait, F., et al., “Topical Indomethacin Protects from UVB and UVA Irriadiation,” Arch. Dermatol. Res. 276:131-132, 1984.
Hakan, et al., “The protective effect of fish oil enema in acetic acid and ethanol induced colitis,” The Turkish Journal of Gasroenterology, 2000, vol. 11, No. 2, pp. 155-161.
Hall, Karla, “Diaper Area Hemangiomas: A Unique Set of Concerns,” http://members.tripod.com/.about.Michelle.sub.—G/diaper.html, Dec. 1, 2008, 8 pages.
Hallstar. Retrieved online on Jun. 4, 2011. <URL:http://www.hallstar.com/pis.php?product=1H022>. 1 page.
Hargreaves, “Chemical Formulation, An Overview of Surfactant-Based Preparations Used in Everyday Life”, The Royal SocietyLV Chemistry, pp. 114-115 (2003).
Harrison, et al., “Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs”, Antivial Res., 15(4):315-322 (1991).
Harrison, et al., “Modification of Immunological Responses and Clinical Disease During Topical R-837 Treatment of Genital HSV-2 Infection”, Antiviral Research, 10:209-224 (1988).
Harrison, et al., “Pharmacokinetics and Safety of Iminquimod 5% Cream in the Treatment of Actinic Keratoses of the Face, Scalp, or Hands and Arms”, Arch. Dermatol. Res., 296(1):6-11 (2004)—Abstract, 1 page.
Harrison, et al., “Posttherapy Suppression of Genital Herpes Simplex Virus (HSV) Recurrences and Enhancement of HSV-Specific T-Cell Memory by Imiquimod in Guinea Pigs”, Antimicrobial Agents and Chemotherapy, 38(9):2059-2064 (1994).
Hashim, et al. “Tinea versicolor and visceral leishmaniasis,” Int J Dermatol., Apr. 1994; 33(4), pp. 258-259 (abstract only).
Heart Failure, the Merck Manual, 2008 <<http://www.merck.com/mmhe/sec03/ch025/ch025a.html>> 12 pages.
Hepburn, NC., “Cutaneous leishmaniasis,” Clin Exp Dermatol, Jul. 2000; 25(5), pp. 363-370 (abstract only).
Hill, Randall M. (Ed.) Silicone Surfactants, Table of Contents and Chapter 7, “Silicone Surfactants: Applicants in the Personal Care Industry,” by David T. Floyd, 1999 (30 pages).
Hormones. Http://www.greenwillowtree.com/Page.bok?file=libido.html. Jan 2001.
http://ibabydoc.com/online/diseaseeczema.asp., Atopic Dermatitis, Copyright 2000, 6 pages.
http://web.archive.org/web/20000106225413/http://pharmacy.wilkes.edu/kibbeweb/lab7.html, Characteristics of Surfactants and Emulsions, Jan. 29, 2010, 5 pages.
http://www.agworkshop.com/p3.asp, AG&Co. Essential oil workshop. 1 page. Accessed Jan. 31, 2010.
Hubbe, Martin. Mini-Encyclopedia of Papermaking Wet-End Chemistry: Additives and Ingredients, their Composition, Functions, Strategies for Use. Retrieved online on Jun. 4, 2011. <URL://http://www4.ncsu.edu/˜hubbe/CSIL.htm>. Feb. 1, 2001. 2 pages.
hydroxyethylcellulose. Http: //terpconnect.umd.edu/-choi/MSDS/Sigma-Aldrich/HYDROXYETHYL%20CELLULOSE, 5 pages, Jan. 14, 2004.
ICI Americas Inc. “The HLB System: A Time-Saving Guide to Emulsifier Selection.” Mar. 1980. pages 1-22.
Ikuta, et al., “Scanning Electron Microscopic Observation of Oil/Wax/Water/Surfacant System”, Journal of SCCJ, 34(4):280-291 (2004)—Abstract, 1 page.
Indomethacin. Retrieved online on Jun. 3, 2011. <URL:http://it03.net/com/oxymatrine/down/1249534834.pdf>. Aug. 15, 2009. 3 pages.
Innocenzi, Daniele et al., “An Open-Label Tolerability and Effacy Study of an Aluminum Sesquichlorhydrate Topical Foam in Axillary and Palmar Primary Hyperhidrosis,” Dermatologic Therapy, vol. 21, S27-S30, 2008.
Izquierdo, P. et al. “Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method.” University of Barcelona. Sep. 17, 2001. 1 page.
Jan. “Troubled Times: Detergent Foam.” http://zetatalk.com/health/theall7c.htm. Accessed Feb. 9, 2012. 2 pages.
Joseph, “Understanding foams & foaming,” University of Minnesota (1997), at http://www.aem.umn.edu/people/faculty/joseph/archive/docs/understandingfoams.pdf, pp. 1-8.
Kalkan, et al., The Measurement of Sweat Intensity Using a New Technique, Tr. J. of Medical Sciences 28, 515-517 (1998).
Kanamoto, et al., “Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery,” J Pharmacobiodyn., Mar. 1988; 11(3):141-5.
Kang, et al., “Enhancement of the Stability and Skin Penetration of Vitamin C by Polyphenol”, Immune Netw., 4(4):250-254 (2004)—Abstract, 1 page.
Karasu, T.B. et al., “Treatment of Patients with Major Depressive Disorder, Second Edition,” pp. 1-78, 2000.
Kathon.TM. CG (product information sheet by Rohm and Haas, Jun. 2006).
Kim, “Stability of Minoxidil in Aqueous Solution”, Yakhak Hoechi, 30(5):228-231 (1986)—Abstract, 1 page.
Kinnunen, “Skin reactions to hexylene glycol,” Contact Dermatitis Sep. 1989; 21(3): 154-8.
Kleber, M.D., H.D. et al., “Treatment of Patients with Substance Use Disorders, Second Edition,” pp. 1-276, 2006.
Koerber, S., “Humectants and Water Activity,” Water Activity News, 2000, ISSN No. 1083-3943.
Kreuter, J. “Nanoparticles and microparticles for drug and vaccine delivery,” J. Anat. (1996) 189, pp. 503-505.
Kumar, J. et ak., “Application of Broad Spectrum Antiseptic Povidone Iodine as Powerful Action: A Review,” Journal of Pharmaceutical Science and Technology vol. 1(2), 2009, 48-58.
Kwak et al. “Study of Complete Transparent Nano-Emulsions which Contain Oils.” IFSCC Conference 2003, Seoul, Korea, Sep. 22-24, 2003. 3 pages.
Lautenschlager, Dr. Hans. “A Closer Look on Natural Agents: Facts and Future Aspects.” Kosmetic Konzept. Kosmetische Praxis. 2006 (no month given). (5), 8-10. 3 pages.
Lebwohl et al. “Treatment of Psoriasis. Part 1. Topical Therapy and Phototherapy.” J Am. Acad. Dermatol. 45:487-498. Oct. 2001.
Lebwohl et al., “A randomized, double-blind, placebo-controlled study of clobestasol propionate 0.05% foam in the treatment of nonscalp psoriasis,” International Journal of Dermatology, 2002, 41(5):269-274.
Lee, et al., “The Stabilization of L-Ascorbic Acid in Aqueous Solution and Water-in-Oil-in-Water Double Emulsion by Controlling pH and Electrolyte Concentration”, J. Cosmet. Sci., 55:1-12 (Jan./Feb. 2004).
Leung, et al., “Bioadhesive Drug Delivery in Water-Soluble Polymers,” American Chemical Society, Chapter 23, 1991, pp. 350-366.
Li, et al., “Solubility Behavior of Imiquimod in Alkanoic Acids”, Abstract 3029, Pharmaceutical Research, vol. 14, No. 11 Supplemental (Nov.), p. S475 (1997), 2 pages.
Licking Vaginal Dryness without a Prescription. Accessed http://www.estronaut.com/a/vag.sub.—dryness.htm on Dec. 14, 2008, 3 pages.
Lippacher, A. et al. “Liquid and Semisolid SLN Dispersions for Topical Application” Rheological Characterization. European Journal of Pharmaceutics and Biopharmaceutics. 58. 2004. pp. 561-567.
Lupo, “Antioxidants and Vitamins in Cosmetics”, Clinics in Dermatology, 19:467-473 (2001).
Martindale, The extra pharmacopoeia [28th] edition, Eds.: Reynolds, J.E.F. and Prasad, A.B., The Pharmaceutical Press, London, pp. 862-864, 1982.
Martindale. 33 ed. London, Bath Press, 2002. pp. 1073 and 1473.
Material Safety Data Sheet, Progesterone, Apr. 26, 2006, 5 pages.
Material Safety Data Sheet, Science Lab.com, Polyethylene Glycol 1000, MSDS, Nov. 6, 2008, 6 pages.
Merck index, 10th edition, Merck & Co., Inc.: Rahway, NJ, 1983, pp. 39 (entry 242 for allantoin).
Merck index, 14th edition, O'Neill, ed., 2006, entry for p-amino benzoic acid.
Merck index, 14th edition, O'Neill, ed., 2006, entry for zinc oxide.
Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition. O'Neil et al eds. Entries 1058, 2350, 6143, and 8803. 2001. 7 pages.
Merck Manual Home Edition. “Excessive Sweating: Sweating Disorders.” Accessed Apr. 14, 2011 at www.merckmanuals.com/home/print/sec18/ch206/ch206c.html. 2 pages.
Merriam Webster Online Dictionary [online] retrieved from http://www.merriam-webster.com/cgi-bin/dictionary?book=dictionary&va=derivative on Jul. 5, 2008; 1 page.
Merriam-Webster Online Dictionaary, 2008, “Mousse,” Merriam-Webster Online, Dec. 8, 2008 http://www.merriam-webster.com/dictionary/mousse, 2 pages.
Messenger, et al., “Minoxidil: Mechanisms of Action on Hair Growth”, British Journal of Dermatology, 150:186-194 (2004).
Metronidazole. www.usp.org/pdf/EN/veterinary/metronidazole.pdf. accessed Sep. 10, 2009, 4 pages.
Metz, et al., “A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy”, Clinical Cancer Research, 10:6411-6417 (2004).
Meucci, et al., “Ascorbic Acid Stability in Aqueous Solutions”, Acta Vitaminol Enzymol, 7(3-4):147-153 (1985)—Abstract, 1 page.
MMP Inc. International Development and Manufacturing, “Formulating specialities,” http://mmpinc.com, 3 pages. Feb. 2, 2010.
Molan, Peter Clark, “World Wide Wounds,” Dec. 2001, 13 pages.
Morgan, Timothy M., et al., “Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles,” Journal of Pharmaceutical Sciences, vol. 87, No. 10, Oct. 1998, pp. 1213-1218.
Neutrogena. Http://www.cosmetoscope.com/2010/04/neutrogea-clinical-with-johnson-johnsons-cytomimic-techology/. Published Apr. 28, 2010. Accessed Sep. 11, 2010, 5 pages.
Nietz, “Molecular orientation at surfaces of solids,” J. Phys. Chem., 1928, 32(2): 255-269.
No Author Listed. “Opitmization of Nano-Emulsions Production by Microfluidization.” European Food Research and Technology. vol. 225, No. 5-6. Sep. 2007. Abstract. 1 page.
Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., May 9, 2008, 27 pages.
Office Action received from the U.S. Patent Office, U.S. Appl. No. 11/430,599, Jul. 28, 2008 (59 pages).
Oil. Dictionary of Chemistry. Editor: DWA Sharp. Copyright 1990.
Olsen, et al., “A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men”, J. Am. Acad Dermatol, 57:767-774 (2007).
OM Cinnamate. http://www.makingcosmetics.com/sunscreens/OM-Cinnamate-p102.html accessed Sep. 26, 2009, 1 page.
Padhi et al., “Phospho-olicines as positive-electrode materials for rechargeable lithium batteries,” J. Electrochemical Soc., 1997, 144(4): 1188-1194.
Pakpayat, et al., “Formulation of Ascorbic Acid Microemulstions with Alkyl Polyglycosides”, European Journal of Pharmaceutics and Biopharmaceutics, 72:444-452 (2009).
Paula. http://ww.cosmeticscop.com/cosmetic-ingredient-dictionary/definition/259/c12-15-alkylbenzoate.aspx. Printed Oct. 24, 2010. 1 page.
Pendergrass, “The shape and dimension of the human vagina as seen in three-dimensional vinyl polysiloxane casts,” Gynecol Obstet. Invest. 1996:42(3):178-82.
Prescription Information for Aldara, Mar. 2007 (29 pages).
prevent. (2007). In The American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/prevent. 1 page.
Psoriasis, http://www.quickcare.org/skin/causes-of0psoriasis.html. Accessed Sep. 9, 2010—3 pages.
Purcell, Hal C. “Natural Jojoba Oil Versus Dryness and Free Radicals.” Cosmetics and Toiletries Manufacture Worldwide. 1988. 4 pages.
Raschke, et al., “Topical Activity of Ascorbic Acid: From In Vitro Optimization to In Vivo Efficacy”, Skin Pharmacology and Physiology, 17(4):200-206 (2004)—Abstract, 1 page.
Ravet et al., “Electroactivity of natural 503-507 and synthetic triphylite,” J. of Power Sources, 2001, 97-98: 503-507.
Raymond, Iodine as an Aerial Disinfectant, Journal of Hygiene, vol. 44, No. 5 (May 1946), pp. 359-361.
Receptacle. Merriam Webster. Http://www.merriam-webster.com/dictionary/receptacle. Accessed Jul. 12, 2011. 1 page.
Richwald, “Imiquimod”, Drugs Today, 35(7):497 (1999)—Abstract, 1 page.
Rieger and Rhein. “Emulsifier Selection/HLB.” Surfactants in Cosmetics. 1997 (no month given). 1 page.
Rosacea, http://clinuvel.com/skin-conditions/common-skin-conditions/rosacea#h0-6-prevention. Accessed Sep. 9, 2010, 5 pages.
Savin, et al., “Tinea versicolor treated with terbinafine 1% solution,” Int J. Dermatol, Nov. 1999; 38(11), pp. 863-865.
Schmidt a., “Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders,” Curtis., Jan. 1997; 59(1), pp. 21-4 (abstract).
Schulze, M.D., Harry “Iodine and Sodium Hypochlorite as Wound Disinfectants,” The British Medical Journal, pp. 921-922, 1915.
Scientific Discussion for the approval of Aldara, EMEA 2005 (10 pages).
Scott as Published in Pharmaceutical Dosage Forms; Disperse Systems, vol. 3, Copyright 1998, 120 pages.
Seborrheic Dermatitis, http://www.cumc.columbia.edu/student/health/pdf/R-S/Seborrhea%20Dermatitis.pdf. Access Sep. 9, 2010, 2 pages.
Shear, et al., “Pharmacoeconomic analysis of topical treatments for tinea infections,” Pharmacoeconomics. Mar. 1995; 7(3); pp. 251-267 (abstract only).
Sheu, et al., “Effect of Tocopheryl Polyethylene Glycol Succinate on the Percutaneous Penetration of Minoxidil from Water/Ethanol/Polyethylene Glycol 400 Solutions”, Drug Dev. Ind. Pharm., 32(5):595-607 (2006)—Abstract, 1 page.
Shim, et al., “Transdermal Delivery of Mixnoxidil with Block Copolymer Nanoparticles”, J. Control Release, 97(3):477-484 (2004)—Abstract, 1 page.
Shrestha et al., Forming properties of monoglycerol fatty acid esters in nonpolar oil systems, Langmuir, 2006, 22: 8337-8345.
Sigma Aldrich, “HLB-Numbers in Lithography Nanopatterning,” http://www.sigmaaldrich.com/materials-science/micro-and-nanoelectronics/l-ithography-nanopatterning/hlb-numbers.html, accessed: Feb. 2, 2009, pp. 1-3.
Sigma-Aldrich, Material Safety Data Sheet, Hydroxyethyl Cellulose, Mar. 3, 2004, 5 pages.
Silicone. Definition. Retrieved Apr. 19, 2011 from http://www.oxforddictionaries.com/definition/silicone?view=uk. 1 page.
Simovic, S. et al., “The influence of Processing Variables on Performance of O/W Emulsion Gels Based on Polymeric Emulsifier (Pemulen ÒTR-2NF),” International Journal of Cosmetic Science, vol. 2(2): abstract only. Dec. 24, 2001, 1 page.
Skin Biology, CP Serum—Copper-Peptide Serum for Skin Regeneration and Reducing Wrinkles, Skin Biology, http;//web.archive.org/web/20030810230608/http://www.skinbio.com/cpserum.-html, Dec. 1, 2008, 21 pages.
Skin Deep Cosmetics. PPG-40-PEG-60 Lanolin Oil http://www.cosmeticsdatabase.com/ingredient/722972/PPG-40-PEG-60—Lanolin—Oil/?ingred06=722972. 3pages.
Smith, Anne. “Sore Nipples.” Breastfeeding Mom's Sore Nipples: Breastfeeding Basics. http://breastfeedingbasics.com/articles/sore-nipples. Accessed Feb. 8, 2012. 9 pages.
Sonneville-Aubrun, O. et al. “Nanoemulsions: A New Vehicle for Skincare Products.” Advances in Colloid and Interface Science. 108-109.. 2004. pages. 145-149.
Squire. J, “A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment ofdandruff/seborrhoeic dermatitis,” Dermatolog Treat. Jun. 2002;13(2):51-60 (abstract only).
Sreenivasa, et al., “Preparation and Evaluation of Minoxidil Gels for Topical Application in Alopecia”, Indian Journal of Pharmaceutical Sciences, 68(4):432-436 (2006), 11 pages.
Stehle et al., Uptake of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear hair follicles, J. Invest. Dermatoll., 2005, 124(4), A101.
Sugisaka, et al., “The Physiochemical Properties of Imiquimod, The First Imidazoquinoline Immune Response Modifier”, Abstract 3030, Pharmaceutical Research, vol. 14, No. 11 Supplemental (Nov.), p. S475 (1997), 2 pages.
Surfactant. Chemistry Glossary. Http://chemistry.about.com/od/chemistryglossary/g/surfactant.htm, 2012, 1 page.
Sweetman, Sean C. Martindale: The Complete Drug Reference. 33rd Edition. London. Pharmaceutical Press. Jun. 21, 2002. pags. 1073 and 1473. 5 pages.
Tadros, Tharwat F. “Surfactants in Nano-Emulsions.” Applied Surfactants: Principles and Applications. Wiley-VCH Verlag GmbH & Co. Weinheim. ISBN: 3-527-30629-3. 2005. pp. 285-308.
Tan et al., “Effect of Carbopol and Polyvinlpyrrolidone on the Mechanical Rheological and Release Properties of Bioadhesive Polyethylene Glycol Gels,” AAPS PharmSciTech, 2000; 1(3) Article 24, 2000, 10 pages.
Tanhehco, “Potassium Channel Modulators as Anti-Inflammatory Agents”, Expert Opinion on Therapeutic Patents, 11(7):1137-1145 (2001)—Abstract, 3 pages.
Tarumoto, et al., Studies on toxicity of hydrocortisone 17-butyrate 21-propionate -1. Accute toxicity of hydrocortisone 17-butyrate 21-propionate and its analogues in mice, rats and dogs (author's trans), J Toxicol Sci., 1981 Jul. 6, 1981; Suppl: 1-16 (Abstract only).
Tata, et al., “Penetration of Minoxidil from Ethanol Propylene Glycol Solutions: Effect of Application Volume on Occlusion”, Journal of Pharmaceutical Sciences, 84(6):688-691 (1995).
Tata, et al., “Relative Influence of Ethanol and Propylene Glycol Cosolvents on Deposition of Minoxidil into the Skin”, Journal of Pharmaceutical Sciences, 83(10):1508-1510 (1994).
Third Party Submission for U.S. Appl. No. 12/014,088, Feb. 4, 2009, 4 pages, cited by other.
Tones-Rodriguez, JM., “New topical antifungal drugs,” Arch Med Res. 1993 Winter; 24(4), pp. 371-375 (abstract).
Toxicology and Carcinogenesis Studies of t-Butyl Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), http://ntp.niehs.nih.gob/?objectid-=0709F73D-A849-80CA-5FB784E866B576D1. Accessed Dec. 9, 2008, 4 pages.
Trofatter, “imiquimod in clinical Practice”, European Journal of Dermatology, 8(7 Supp.):17-19 (1998)—Abstract, 1 page.
Tsai, et al., “Drug and Vehicle Deposition from Topical Applications: Use of in Vitro Mass Balance Technique with Minosidil Solutions”, J. Pharm. Sci., 81(8):736-743 (1992)—Abstract, 1 page.
Tsai, et al., “Effect of Minoxidil Concentration on the Deposition of Drug and Vehicle into the Skin”, International Journal of Pharmaceutics, 96(1-3):111-117 (1993)—Abstract, 1 page.
Tsai, et al., “Influence of Application Time and Formulation Reapplication on the Delivery of Minoxidil through Hairless Mouse Skin as Measured in Franz Diffusion Cells”, Skin Pharmacol., 7:270-277 (1994).
Tyring, “Immune-Response Modifiers: A New Paradigm in the Treatment of Human Papillomavirus”, Current Therapeutic Research, 61(9):584-596 (2000)—Abstract, 1 page.
Tzen, Jason T.C. et al. “Surface Structure and Properties of Plant Seed Oil Bodies.” Department of Botany and Plant Sciences, University of California, Riverside, California 92521. Apr. 15, 1992. 9 pages.
Uner, M. et al. “Skin Moisturizing Effect and Skin Penetration of Ascorbyl Palmitate Entrapped in Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Incorporated into Hydrogel.” Pharmazie. 60. 2005. 5 pages.
Veron, et al., “Stability of Minoxidil Topical Formulations”, Ciencia Pharmaceutica, 2(6):411-414 (1992), Abstract, 1 page.
Wermuth, C.G. “Similarity in drugs: reflections on analogue design,” Drug Discovery Today, vol. 11, Nos. 7/8, Apr. 2006, pp. 348-354.
Williams, “Scale up of an olive/water cream containing 40% diethylene glycol momoethyl ether”, Dev. Ind. Pharm., 26(1):71-77 (2000).
Wormser et al., Protective effect of povidone-iodine ointment against skin lesions induced by sulphur and nitrogen mustards and by non-mustard vesicants, Arch. Toxicol., 1997, 71, 165-170.
Wormser, Early topical treatment with providone-iodine ointment reduces, and sometimes prevents, skin damage following heat stimulus, Letter to the Editor, Burns 24, pp. 383, 1998.
Yamada and Chung, “Crystal Chemistry of the Olivine-Type Li(MnyFe1-y)PO4 and (MnyFe1-y)PO4 as Possible 4 V Cathopde Materials for Lithium Batteries,” J. Electrochemical Soc., 2001, 148(8): A960-967.
“Coal tars and coal-tar pitches,” Report on Carcinogens, Twelfth Edition, 2011, 3 pages.
Adisen et al. “Topical tetracycline in the 7:953-5 treatment of acne vulgaris,” J Drugs Dermatol., 2008, 7:953-5.
Baskaran et al., “Poloxamer-188 improves capillary blood flow and tissue viability in a cutaneous burn wound,” J. Surg. Res., 2001, 101(1):56-61.
Bell-Syer et al. “A systematic review of oral treatments for fungal infections of the skin of the feet,” J. Dermatolog. Treat., 2001, 12:69-74.
Boehm et al. 1994, “Synthesis of high specific activity [.sup.3 H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties,” J. Med. Chem., 37:408-414.
Carapeti et al., “Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects,” Dis Colon Rectum, 2000, 43(10):1359-62.
Cook and Mortensen, “Nifedipine for 43(3):430-1 treatment of anal fissures,” Dis Colon Rectum, 2000, 43(3):430-1.
Dumortier et al., “A review of poloxamer 407 pharmaceutical and pharmacological characteristics,” Pharmaceutical Res., 2006, 23(12):2709-2728.
Ebadi et al., “Healing effect of topical nifedipine on skin wounds of diabetic 11(1):19-22 rats,” DARU, 2003, 11(1):19-22.
Effendy and Maibach. “Surfactants and Experimental Irritant Contact Dermatitis.” Contact Dermatol., 1995, 33:217-225.
Elias and Ghadially, “The aged epidermal permeability barrier,” Clinical Geriatric Medicine, Feb. 2002, pp. 103-120.
Fantin et al., “Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (Quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus,” Antimicrob Agents and Chemothery,. 1999, 39:400-405.
Fluter et al., “Glycerol accelerates recovery of barrier function in vivo,” Acta Derm. Venereol,. 1999, 79:418-21.
Garti et al. “Sucrose Esters microemulsions,” J. Molec. Liquids, 1999, 80:253-296.
Hammer et al. “Anti-Microbial Activity of Essential Oils and other Plant Extracts,” J. Applied Microbiology, 1999, 86:985-990.
Hwang et al. “Isolation and identification of mosquito repellents in Artemisia vulgaris” J. Chem. Ecol., 11: 1297-1306, 1985.
Knight et al., “Topical diltiazem ointment in the treatment of chronic anal fissure,” Br. J. Surg., 2001, 88(4):553-6.
Kucharekova et al., “Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction,” Contact Dermatitis, Jun. 2002, pp. 331-338.
Leive et al, “Tetracyclines of various hydrophobicities as a probe for permeability of Escherichia coli outer membrane,” Antimicrobial Agents and Chemotherapy, 1984, 25:539-544.
Luepke and Kemper, “The HET-CAM Test: An Alternative to the Draize Eye Test,” FD Chem. Toxic., 1986, 24:495-196.
Osborne and Henke, “Skin Penetration Enhancers Cited in the Technical Literature,” Pharm. Technology, Nov. 1997, pp. 58-86.
Padi. “Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms,” Eur J. Pharmacol, 2008, 601:79-87.
Palamaras and Kyriakis, “Calcium antagonists in dermatology: a review of the evidence and research-based studies,” Derm. Online Journal, 2005, 11(2):8.
Passi et al., Lipophilic antioxidants in human sebum and aging, Free Radical Research, 2002, pp. 471-477.
Perrotti et al., “Topical Nifedipine With Lidocaine Ointment vs. Active Control for Treatment of Chronic Anal Fissure,” Dis Colon Rectum, 2002, 45(11):1468-1475.
Repa et al. “All-trans-retinol is a ligand for the retinoic acid receptors,” Proc. Natl. Acad Sci, USA, 90:7293-7297, 1993.
Ruledge, “Some corrections to the record on insect repellents and attractants,” J. Am. Mosquito Control Assoc, 1988, 4(4): 414-425.
Sakai et al., “Characterization of the physical properties of the stratum corneum by a new tactile sensor,” Skin Research and Technology, Aug. 2000, pp. 128-134.
Schaefer, “Silicone Surfactants,” Tenside, Surfactants, Deterg., 1990, 27(3): 154-158.
Simoni et al., “Retinoic acid and analogs as potent inducers of differentiation and aptosis. New promising chemopreventive and chemotherapeutic agents in oncology,” Pure Appl Chem., 2001, 73(9):1437-1444.
Smith, “Hydroxy acids and skin again,” Soap Cosmetics Chemical Specialties, 1993, pp. 54-59.
Solans et al. “Overview of basic aspects of microemulsions,” Industrial Applications of Microemulsions, Solans et al Eds, New York, 1997, 66:1-17.
Squillante et al., “Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin,” European J. Pharm. Biopharm., 1998, 46(3):265-71.
Todd et al. “Volatile Silicone Fluids for Cosmetics,” 91 Cosmetics and Toiletries, 1976, 27-32.
Torma et al., “Biologic activities of retinoic acid and 3, 4-dehydroretinoic acid in human keratinoacytes are similar and correlate with receptor affinities and transactivation properties,” J. Invest. Dermatology, 1994, 102: 49-54.
USP23/NF 18 The United States Pharmacopeia: The National Formulary, US Pharmacopoeia, 1995, p. 10-14.
Van Slyke, “On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of buffer value to the of the buffer solution,” J. Biol. Chem., 1922, 52:525-570
Van Cutsem et al., “The antiinflammatory efects of ketoconazole,” J. AM. ACAD. Dermatol., 1991, 25(2 pt 1):257-261.
Wang and Chen, “Preparation and surface active properties of biodegradable dextrin derivative surfactants,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2006, 281(1-3):190-193.
Weindl et al., “Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects,” Skin Pharmacology and Physiology, 2004, 17: 207-213.
Xynos et al., “Effect of nifedipine on rectoanal motility,” Dis Colon Rectum, 1996, 39(2):212-216.
Yamada et al., “Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats,” J. Pharmacol. Exp. Ther., 2003, 307(1)17-23.
Paragraph E.3.1 of regulation (EC) No. 2003 (See Directive 67/548/EEC OJ 196, 16.8, 1967, p. 1.
Tzen et al., Lipids, proteins and structure of seed oil bodies from diverse species; Plant Physiol., 1993, 101:267-276.
Brown et al. “Structural dependence of flavonoid interactions with Cu2+ inos: implications for their antioxidant properties,” Biochem. J., 1998, 330:1173-1178.
Cloez-Tayarani. et al., “Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5- hydroxytryptamine2A receptors,” Int. Immunol., 2003, 15:233-40.
“Mineral oil USP,” Chemical Abstracts Service Registry No. 8012-95-1, 2011, 7 pages.
“Tea tree oil,” Chemical Abstract No. 68647-73-4, 2012, 2 pages.
Lin et al., “Ferulic acid stabilizes a solution of vitamins c and e and doubles its protoprotection of skin,” J Invest Dermatol, 2005, 125:826-32.
International Preliminary Examination Report from PCT/IL01/00025, dated Aug. 27, 2001, and International Search Report dated Jun. 22, 2001, 6 pages.
Related Publications (1)
Number Date Country
20100137198 A1 Jun 2010 US
Provisional Applications (1)
Number Date Country
60216162 Jul 2000 US
Divisions (1)
Number Date Country
Parent 09653267 Aug 2000 US
Child 10392071 US
Continuations (2)
Number Date Country
Parent 11294318 Dec 2005 US
Child 12705219 US
Parent 10392071 Mar 2003 US
Child 11294318 US